

A novel alpha-synuclein K58N missense variant in a patient with Parkinson's disease

Mohammed Al-Azzani^{1†}, Sandrina Weber^{2†}, Nagendran Ramalingam³, Maria Ramón¹, Liana Shvachiy¹, Gonçalo Mestre¹, Michael Zech^{4,5,6}, Kevin Sicking^{7,8}, Alain Ibáñez de Opakua⁹, Vidyashree Jayanthi³, Leslie Amaral^{1,10}, Aishwarya Agarwal¹¹, Aswathy Chandran¹¹, Susana R. Chaves¹⁰, Juliane Winkelmann^{4,5,12,13}, Claudia Trenkwalder^{14,15}, Maike Schwager¹⁶, Silke Pauli¹⁶, Ulf Dettmer³, Claudio O. Fernández¹⁷, Janin Lautenschläger¹¹, Markus Zweckstetter^{9,18}, Ruben Fernandez Busnadiego^{7,8,19,20}, Brit Mollenhauer^{2,15*}, and Tiago Fleming Outeiro^{1,9,21,22*}

¹University Medical Center Göttingen, Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, Göttingen, Germany.

²Department of Neurology, University Medical Center Goettingen, Goettingen, Germany.

³Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United State.

⁴Institute of Neurogenomics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.

⁵Institute of Human Genetics, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.

⁶Institute for Advanced Study, Technical University of Munich, Garching, Germany.

⁷University Medical Center Göttingen, Institute for Neuropathology, Göttingen, 37077 Germany.

⁸Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.

⁹German Center for Neurodegenerative Diseases (DZNE), Von-Siebold-Str. 3a, 37075 Göttingen, Germany.

25 ¹⁰ CBMA – Centre of Molecular and Environmental Biology, School of Sciences, University of
26 Minho, 4710-057 Braga, Portugal.

27 ¹¹ Cambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical
28 Campus, The Keith Peters Building, Hills Road, Cambridge, CB2 0XY, UK.

29 ¹²Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.

30 ¹³German Center for Mental Health (DZPG), partner site Munich-Augsburg, Munich-Augsburg,
31 Germany.

32 ¹⁴Department of Neurosurgery, University Medical Centre Goettingen, Goettingen, Germany.

33 ¹⁵Paracelsus-Elena-Klinik, Kassel, Germany.

34 ¹⁶Institute of Human Genetics, University Medical Center Göttingen, Göttingen, Germany.

35 ¹⁷Max Planck Laboratory for Structural Biology, Chemistry and Molecular Biophysics of Rosario
36 (MPLbioR, UNR-MPINAT), Partner Laboratory of the Max Planck Institute for Multidisciplinary
37 Sciences (MPINAT, MPG). Centro de Estudios Interdisciplinarios, Universidad Nacional de
38 Rosario, Rosario, Argentina.

39 ¹⁸Department for NMR-based Structural Biology, Max Planck Institute for Multidisciplinary
40 Sciences, Am Faßberg 11, 37077, Göttingen, Germany.

41 ¹⁹Cluster of Excellence “Multiscale Bioimaging: from Molecular Machines to Networks of
42 Excitable Cells” (MBExC), University of Göttingen, Göttingen, 37077, Germany

43 ²⁰Faculty of Physics, University of Göttingen, Göttingen, 37077, Germany

44 ²¹Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle
45 University, Framlington Place, Newcastle Upon Tyne, NE2 4HH, UK.

46 ²²Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.

47 †**Co-first authors**

48

49 ***Co-corresponding authors:**

50 Prof. Dr. Tiago Fleming Outeiro

51 Email: tiago.outeiro@med.uni-goettingen.de

52

53 Prof. Dr. Brit Mollenhauer

54 Email: brit.mollenhauer@med.uni-goettingen.de

55

56 **Running title:** A novel alpha-synuclein K58N variant in PD

57

58 **Keywords:** Alpha-synuclein; Parkinson's disease; genetics; neurodegeneration; protein
59 aggregation

60

61

62

63

64

65

66

67

68

69

70

71

72

73 **Abstract**

74 Mutations and multiplications in the *SNCA* gene, encoding alpha-synuclein (aSyn), are associated
75 with familial forms of Parkinson's disease (PD). We report the identification of a novel *SNCA*
76 missense mutation (NM_000345.4, cDNA 174G>C; protein K58N) in a PD patient using whole
77 exome sequencing, and describe comprehensive molecular and cellular analyses of the effects of
78 this novel mutation. The patient exhibited typical sporadic PD with early onset and a benign
79 disease course. Biophysical studies revealed that the K58N substitution causes local structural
80 effects, disrupts binding to membranes, and enhances aSyn in vitro aggregation. K58N aSyn
81 produces fewer inclusions per cell, and fails to undergo condensate formation. The mutation
82 increases the cytoplasmic distribution of the protein, and has minimal effect on the dynamic
83 reversibility of serine-129 phosphorylation. In total, the identification of this novel mutation
84 advances our understanding of aSyn biology and pathobiology.

85

86

87

88

89

90

91

92

93

94

95

96

97

98 **Introduction**

99 Parkinson's disease (PD) is an age-associated neurodegenerative disorder that classically
100 manifest clinically by a triad of cardinal motor symptoms of tremor, rigidity, and bradykinesia, as
101 well as non-motor symptoms like depression, autonomic dysfunction and dementia (1, 2).
102 Neuropathologically, PD is marked by the progressive degeneration of dopaminergic neurons in
103 in the substantia nigra and the presence of Lewy bodies (LBs), which are intraneuronal inclusions
104 predominantly composed of aggregated alpha-synuclein (aSyn) (3–6). In addition to PD,
105 misfolding and aggregation of aSyn into protein inclusions is present in other neurodegenerative
106 disorders grouped together as synucleinopathies, such as dementia with Lewy bodies (DLB) and
107 multiple system atrophy (MSA). Importantly, increasing evidence points to different structural
108 organization of aSyn fibrils within inclusions that varies according to the synucleinopathy (7–9).

109 aSyn, an intrinsically disordered protein, has been a significant focus of neuroscience research
110 not only due to its central role in PD and related synucleinopathies, but also because of its
111 abundance and function in the nervous system. aSyn is primarily concentrated in the presynaptic
112 terminals of neurons, but is also present in other cellular compartments including the nucleus, and
113 is thought to interact with membranes adopting helical conformations and tetrameric structures
114 (10, 11). Nevertheless, the precise physiological functions of aSyn are still poorly understood,
115 especially in what concerns its function in non-neuronal cells.

116 In pathological conditions, aSyn is thought to misfold and accumulate, forming pathological
117 aggregates that disrupt cellular homeostasis, in a process that may ultimately cause neuronal cell
118 death. Dopaminergic neurons in the substantia nigra seem particularly vulnerable to the toxic
119 damage of pathological aSyn aggregates, although the underlying mechanisms remain unclear.
120 While aSyn aggregation has been typically considered the driver of neurodegeneration, other
121 theories suggest that the loss of functional monomeric aSyn due to aggregation, also known as

122 synucleinopenia, may lead to disease progression (12, 13). In reality, a combination of
123 proteinopathy and proteinopenia are likely to contribute to disease.

124 Missense mutations in *SNCA*, the gene that encodes aSyn, are linked to familial forms of PD,
125 suggesting that determining the molecular effects of such mutations may prove important for our
126 understanding of the pathological underpinnings of the disease. In fact, since the discovery of the
127 first *SNCA* mutation encoding for the A53T substitution (3), the field of PD genetics has enabled
128 the identification of several other *SNCA* mutations as well as mutations in several other genes in
129 PD (14, 15). Several variants of aSyn have been linked to familial forms of PD and include, for
130 example, G14R, V15A, A30G, A30P, E46K, H50Q, G51D, A53T, A53E, A53V, T72M,
131 highlighting the importance of aSyn in PD (3, 6, 16–24). However, mutations in the *SNCA* gene
132 are extremely rare and account for only 0.1-0.2% of cases (14). In addition, duplications or
133 triplications of the chromosomal region containing the *SNCA* gene are also associated with
134 familial forms of PD (25). These multiplications are consistent with a dose-dependent effect, as
135 *SNCA* triplications cause a fully penetrant and severe phenotype with early onset and common
136 non-motor symptoms like depression, psychosis and cognitive decline (26, 27), while duplications
137 on the other hand, are associated with a more variable clinical presentation, and more often
138 present with Dementia with Lewy bodies rather than PD (26). Missense mutations are generally
139 rarer than duplications (15, 28), and are associated with a broad clinical spectrum that ranges from
140 presentations resembling idiopathic PD, to more complex phenotypes, with atypical signs (29),
141 resembling atypical PD or other neurodegenerative disorders. Consistently, our group has recently
142 described the novel variant G14R, that is associated with an atypical, rapidly progressive
143 phenotype and widespread neuronal loss in combination with frontotemporal lobar degeneration-
144 associated aSyn pathology (24). To date, only a limited number of missense variants have been
145 reported, including variants with unresolved pathogenic relevance and variants that have yet to
146 undergo independent replication (21, 30, 31) . In addition to the clinical heterogeneity, the

147 identification of *SNCA* missense variants is hampered by the fact that some variants demonstrate
148 incomplete penetrance (16, 32), resulting in negative family histories. Consequently, validating
149 known variants and identifying novel ones are crucial for improving diagnostic accuracy and for
150 informing genetic counseling. Furthermore, *SNCA* missense variants are of tremendous interest
151 for researchers because of their potential to expand our understanding of the molecular
152 mechanisms underlying aSyn aggregation as well as pathological and physiological properties,
153 including phosphorylation at S129 (pS129) (33, 34). For instance, different missense variants
154 have been associated with increased or decreased pathologic properties like aggregation and
155 phosphorylation status (24, 35–37). Thus, investigating these variants offers an invaluable
156 opportunity to advance our knowledge of the physiological and pathophysiological roles of aSyn.

157 In this study, we identified a novel heterozygous missense mutation in a case of familial
158 PD and provide a detailed description of the clinical phenotype and molecular effects.

159

160 **Results**

161 **Clinical presentation**

162 The index patient is a male Caucasian that presented initial motor symptoms approximately in his
163 late 30s, with left-sided rest tremor, reduced arm swing and mild bradykinesia on the left side. He
164 was diagnosed with early-onset PD (EOPD) in his early 40s. A dopamine transporter Imaging
165 showed asymmetrical decrease consistent with PD, and no signs indicative of atypical PD or other
166 neurologic disorders were found on clinical examination. After a good initial response to
167 dopamine agonists and dopamine, the patient developed motor-fluctuations with end-of-dose
168 wearing-off, trunk dyskinesias in the on-phase and freezing-of-gait. Marked dystonia was present
169 in the left arm and leg. 13 years after PD diagnosis, he was evaluated for deep brain stimulation
170 (DBS). At that time, non-motor symptoms included excessive daytime sleepiness, fatigue and
171 depression. Comprehensive neuropsychologic assessment found no signs of cognitive dysfunction

172 and a repeated MRI showed no pathologic findings or signs consistent with atypical PD.
173 Presurgical levodopa-response as evaluated by levodopa-challenge test was highly effective, with
174 an improvement of UPDRS-III of 78%. The patient received bilateral DBS of the subthalamic
175 nucleus that reduced the severity of motor fluctuations, freezing, and tremor. Post-surgical follow-
176 up 3 years after DBS implantation showed sustained good effects on motor-symptoms, overall
177 good cognition with MMSE 30/30 but re-emergence of moderate motor-fluctuations. The family
178 history was positive, and both a parent and a grandparent were affected by PD. Both relatives
179 were already deceased but were reported to have had no atypical symptoms and no dementia.

181 **Whole-exome sequencing identifies aSynp.K58N point mutation**

182 The patient was selected for genetic testing by whole-exome sequencing (WES) due to the early
183 onset of PD and the positive family history. WES identified a novel heterozygous missense
184 variant in *SNCA* (NM_000345.4, cDNA 174G>C; protein K58N) (Fig. S1 A and B). The variant
185 was not annotated in the genomic databases gnomAD and the PD Variant Browser. It causes a
186 missense substitution in a phylogenetically highly conserved region (Fig. S1 C) and is predicted
187 as deleterious by several in-silico prediction algorithms (CADD:31, PolyPhen-2: 0.994,
188 PrimateAI: 0.8337, REVEL: 0.653).

190 **K58N mutation causes a reduction in α -helical content, impairing its interaction with** 191 **liposomes**

192 In order to study the impact of K58N mutation on the structural and membrane-binding properties
193 characteristics of aSyn, we employed NMR spectroscopy and circular dichroism (CD) using
194 recombinantly prepared monomeric WT and K58N aSyn. The two-dimensional NMR $^1\text{H}/^{15}\text{N}$ -
195 correlation spectra for both proteins revealed minimal signal spread as expected for IDPs (Fig. 1
196 A). Spectral comparison showed that the majority of the cross peaks for both variants aligned

197 together except for those linked to residues located around the mutation site (Fig. 1 B-D). The
198 disturbances in the NMR signal shifts and intensity were restricted to the vicinity of the K58N
199 mutation as shown in (Fig. 1 B-D).

200 To gain insight into how this could affect the local conformation of K58N aSyn, we calculated the
201 secondary structure from NMR chemical shifts around the mutation area. Interestingly, we
202 observed a reduction in the amount of α -helical content with the K58N mutation in that region
203 (Fig. 1 E). Furthermore, MD simulations of the aSyn peptide G51-N65 either containing the WT
204 lysine or an asparagine at position 58 reproduced the difference observed in the experimental
205 NMR data of the full-length protein showing a decrease in α -helix content for the mutant, albeit
206 with different total values (Fig. 1 F). The findings from both experimental and simulation
207 demonstrate that K58N mutation impact the helical propensity surrounding the mutation site (Fig.
208 1 E and G).

209 aSyn is known to form α -helical structures upon binding to membranes. Therefore, we
210 investigated the effect of K58N mutation on its interactions with membranes by incubating both
211 WT and K58N aSyn with increasing amounts of liposomes and utilizing CD, a well-established
212 technique for monitoring the transition of aSyn into membrane-bound α -helical conformations
213 (38–40). The exposure to liposomes resulted in a shift from random coil into α -helical structure
214 for both variants (Fig. 1 H and I). However, analysis of the change in the ellipticity at 222 nm
215 revealed that K58N mutation exhibited a lower tendency to adopt α -helical conformations when
216 exposed to liposomes reflecting a reduction of the binding to liposomes (Fig. 1 J). In summary,
217 the NMR data shows that the α -helical content is reduced by the mutation in the monomeric state,
218 which may explain the decreased liposome binding, as the liposome-bound aSyn tends to form
219 alpha-helix in that region.

220

221 **Effect of the K58N mutation on aSyn aggregation in vitro**

222 A central pathological hallmark in PD and other synucleinopathies is the accumulation of aSyn
223 into insoluble aggregates. Therefore, we investigated the aggregation propensity of the K58N
224 variant in comparison to WT aSyn. To check this, we initially assessed the aggregation propensity
225 of K58N variant employing various computational prediction algorithms (41–43). These
226 algorithms showed increase in β -strand content, and a higher tendency in the aggregation
227 properties for K58N aSyn (Fig. S2). Experimentally, recombinant WT and K58N aSyn were
228 incubated under shaking conditions to monitor the fibrillization kinetics of both proteins,
229 following an in vitro ThT-based aggregation assay protocol. Interestingly, the K58N showed a
230 higher ThT aggregation profile compared with WT aSyn (Fig. 2 A-B and D). Furthermore, the
231 K58N variant demonstrated different aggregation kinetics, with a shorter $t_{1/2}$ suggesting a faster
232 rate of fibril formation (Fig. 2 C). These findings prompted us to perform detailed cryo-EM
233 analysis of the morphological, organizational, and structural features of fibrils prepared by both
234 variants. As previously reported (24), WT a-Syn fibrils adopted two similarly populated
235 conformations, consisting of one (1PF) or two protofilaments (2PF) respectively (Fig. 3A, C; Fig.
236 S3). 3D reconstruction was only successful for 2PF fibrils, resulting in a structure with 2.7 Å
237 global resolution (Fig. 3 E; Fig. S3; Fig. S4) that enabled building of an atomic model. This
238 model displays a double-arrow fold previously observed in other studies, such as “polymorph 2A”
239 reported by (44). Similar to that structure, our model features a salt bridge between lysine 45
240 (K45) and glutamic acid 57 (E57) that stabilizes the inter-protofilament interface (Fig. 3G, H).
241 The protofilament fold itself is nearly identical to those described as “polymorph L2A and L2B”
242 by (45) and “protofilament fold B” by (46). However, in these cases, the inter-protofilament
243 interactions differ.

244 In contrast, K58N adopted almost exclusively 2PF conformations (Fig. 3B, D; Fig. S5). An
245 atomic model based on the 3D reconstruction of these fibrils at 3.7 Å global resolution revealed a
246 similar protofilament fold as in WT fibrils (Fig. 3F, I, J, Fig. S4). However, K58N fibrils present

247 a higher twist (-1.29 degrees vs -0.81 degrees in WT fibrils), and a slightly shifted protofilament
248 interface, possibly due to the proximity of the mutation site (K58) to the interface stabilizing
249 residue (E57). Additionally, no density for residues 14-25 was visible at the periphery of mutant
250 fibrils (Fig. 3G-J). Altogether, these data indicate that the K58N mutation displaces the
251 conformational equilibrium of a-Syn fibrils towards a 2PF structure reminiscent of that observed
252 for WT.

253

254 **K58N mutation alters aSyn inclusion number and size in a cellular model**

255 After studying the impact of K58N mutation on aggregation of aSyn in vitro, we next explored
256 whether a similar aggregation tendency can be observed under cellular environment. To this end,
257 we employed the SynT/Sph1 model, a well-recognized methodology that has been used regularly
258 to study aSyn aggregation in cells (47). Human neuroglioma cells (H4) were first co-transfected
259 with WT or K58N SynT variants and Sph1 followed by immunostaining to assess inclusion
260 formation 48 hours post-transfection. Interestingly, cells expressing K58N SynT mutation
261 exhibited a significant decrease in the number of aSyn inclusions in comparison to cells
262 expressing WT aSyn (Fig. 4 A and B). The inclusions observed in K58N transfected cells were
263 smaller in size (Fig. 4 C). Moreover, a significant increase in the percentage of cells without
264 inclusions was observed in cells expressing K58N version (Fig. S6).

265

266 **K58N aSyn shows decreased phase separation**

267 We further explored the impact of this novel mutation on aSyn phase separation properties, a
268 critical factor that is thought to play a role in its functional and pathological behavior. We find
269 that K58N aSyn undergoes only minimal droplet formation compared to aSyn wild-type (WT)
270 when tested under otherwise same conditions (Fig. 5 A). This is recapitulated at a quantitative

271 scale, testing aSynK58N phase separation using turbidity measurements in the presence of Ca²⁺
272 and varying PEG concentrations (Fig. 5 B).

273 We next expressed aSyn YFP with VAMP2 in HeLa cells, where VAMP2 induces aSyn phase
274 separation as previously shown (48). Here, WT aSyn YFP shows condensate formation, however
275 K58N aSyn YFP fails to form condensates exhibiting a homogenous cytosolic distribution (Fig. 5
276 C). Quantitative evaluation confirms the absence of condensate formation for the K58N aSyn
277 variant (Fig. 5 D).

278

279 **Effects of the K58N mutation on aSyn S129 phosphorylation**

280 There is increasing evidence that serine-129 phosphorylation (pS129) of aSyn is not only
281 associated with pathology but also influences the physiological function of aSyn (34). Therefore,
282 we investigated whether the K58N mutation alters the pS129 status. To address this, we employed
283 lentiviral vectors to express either human WT or K58N variants in primary aSyn knockout
284 (*SNCA*^{-/-}) rat cortical cultures (Fig. 6 A). We first checked the levels of pS129 in the absence of
285 neuronal stimulation. Compared to WT aSyn, K58N mutant exhibited a significant reduction in
286 basal pS129 (Fig. 6 B). Recent studies have shown that familial PD-associated aSyn mutants with
287 reduced membrane (M) localization is often associated with lower basal pS129 levels (34). Given
288 the observed decrease in pS129 levels observed here for K58N mutant, we hypothesized that this
289 decrease could be attributed to increased solubility or, in other words, decreased membrane
290 association (M). In line with this, we observed that the K58N mutation was enriched in the
291 cytosolic fraction (C) (GAPDH fraction, ~ 62%) (Fig. 6 C and D), supporting the idea that
292 reduced membrane association contributes to lower pS129 levels.

293 Phosphorylation of S129 also has been recently reported to be an activity-dependent, dynamic
294 physiological process. According to these studies, pS129 is elevated following neuronal
295 stimulation and then returns to baseline once the stimulus dampens or when inhibited in a

296 dynamic reversible process (34). Importantly, rodent neuron cultures expressing PD-associated
297 A30P and E46K aSyn mutants showed impaired dynamic reversibility of pS129 (49). To assess
298 the effect of the K58N PD-associated mutation on the dynamic reversibility of pS129, we exposed
299 WT or K58N aSyn transduced rat *SNCA*^{-/-} cortical neurons to neuronal stimulation, inhibition,
300 or a combination of stimulation followed by inhibition (Fig. 6 E). At DIV 17-21, cortical cultures
301 were stimulated with picrotoxin (PTX), a GABA_A receptor antagonist, to stimulate neuronal
302 activity and inhibited by the sodium channel blocker, tetrodotoxin (TTX). Consistent with our
303 previous observations, the exposure of neurons to PTX for 2h and 4h significantly increased
304 pS129 levels in WT neurons, while neuronal inhibition through TTX decreased the basal levels by
305 approximately 30%. The TTX inhibition 2h post-PTX stimulation effectively reversed activity-
306 dependent pS129 elevation (Fig. 6 F). K58N neurons followed a comparable pattern of activity-
307 dependent pS129 response (Fig. 6 G). Interestingly, however, PTX treatment for 4h induced a
308 more pronounced increase in pS129 in K58N aSyn neurons compared to that of WT, relative to
309 basal levels (Fig. 6 H). Then, we compared the 4h PTX stimulation combined with TTX
310 inhibition introduced midway to 2h or 4h PTX stimulation in order to evaluate the dynamic
311 reversibility of pS129. The percentage of irreversible pS129 levels in PTX/TTX-treated neurons
312 was comparable between K58N and WT aSyn relative to PTX stimulation for 2h (Fig. 6 K).
313 However, after 4h of PTX stimulation, a lower proportion of irreversible in K58N neurons
314 compared to WT aSyn expressing neurons (Fig. 6 L). We assessed the sensitivity of K58N
315 transduced neurons to TTX inhibition under unstimulated conditions and found no significant
316 differences between K58N and WT neurons (Fig. 6 I). In conclusion, our findings indicate that
317 activity-dependent pS129 is altered in the disease-associated K58N aSyn mutant, with a
318 pronounced effect in response to prolonged neuronal activity.

319

320 **K58N is more cytosolic without changing cytotoxicity in yeast cells**

321 To investigate how the K58N aSyn mutation affects cellular distribution and cytotoxicity, we
322 used the well-established budding yeast model to associate subcellular localization with toxicity
323 (50). In our results we observed that the K58N aSyn is predominantly localized to the cytoplasm
324 in yeast cells, in contrast to WT aSyn, which tended to form cytoplasmic inclusions (Fig. 7 A).
325 Despite the different subcellular localization, the K58N and WT aSyn presented identical
326 toxicities (Fig. 7 B).

327

328 **Discussion**

329 Here, we report the discovery of missense mutation K58N in the *SNCA* gene and provide a
330 detailed description of the associated clinical phenotype and molecular effects of this novel
331 mutation. The variant was identified through WES in a patient with EOPD and a positive family
332 history, both of which raised the suspicion of an underlying genetic cause. Although both affected
333 relatives were already deceased, and no DNA was available to confirm the mutation, the
334 pathogenic relevance of K58N is supported by (1) the absence of K58N in genomic databases, (2)
335 the disruption of a highly conserved amino acid residue, (3) the prediction of a pathogenic effect
336 by different in-silico tools, and most importantly, (4) the results of the molecular characterization,
337 that are discussed in detail further down. According to ACME (American College of Medical
338 Genetics) guidelines (51), the variant is classified as *likely pathogenic*.

339 The clinical presentation and progression were similar to idiopathic PD, with a good and
340 sustained levodopa-response and the lack of motor- and non-motor-symptoms indicating atypical
341 PD. Both father and grandfather were also diagnosed with PD and even though both were already
342 diseased and could not be examined, the medical history provided by the index patient was in
343 accordance with idiopathic PD. Regarding the phenotypic spectrum of known *SNCA* missense
344 mutations, manifestations that are indistinguishable from idiopathic PD as well as atypical and
345 more complex syndromes have been described (29). While atypical symptoms are for example

346 common in carriers of G51D (18, 52), they are rarely described in carriers of A30P and A30G
347 (22, 53). Additionally, both A30P and A30G seem to lead to an overall more benign disease
348 course compared to other missense mutations, which is similar to our identified mutation.
349 However, cognitive decline was a common feature in both carriers of A30P and A30G and could
350 even precede the onset of motor-symptoms, which was not observed in our present case. Another
351 feature that is often seen across all *SNCA* mutations (including multiplications) are motor-
352 fluctuations, that are present in around two thirds of cases (26). In the patient with K58N, the
353 severity of motor- fluctuations eventually led to the implantation of bilateral nucleus
354 subthalamicus DBS. The patient profited from this intervention, with a good overall effect on
355 motor-symptoms and motor-fluctuations. Thus, our study provides valuable information about
356 beneficial DBS in K58N *SNCA*, even though the long-term effect has yet to be assessed, as
357 motor-fluctuations seemed to re-emerge 4 years after DBS. A growing body of research suggest
358 that the outcome of DBS is influenced by the presence of different genetic mutations (54). So far,
359 data on DBS in *SNCA* missense variants is rare and limited to a few cases, with variable results
360 (22, 55–58). Whilst all cases had good short-term benefits from subthalamic nucleus DBS,
361 especially on motor-fluctuations, two unrelated patients with A53E experienced rapid progression
362 of motor- and non-motor symptoms after surgery (55, 57). Re-emergence of motor-fluctuations
363 after DBS was also reported in two patients with A30G (after 3 years) (22) and E46K (unknown
364 interval) (58), respectively, but both cases had an overall less aggressive progression than the
365 A53E cases. Additional data is needed to elucidate the relationship between *SNCA* mutations and
366 DBS outcome, as this has important implications for patient counseling and indication for DBS.
367 Most aSyn PD-associated mutations identified thus far occur in the N-terminal domain of aSyn.
368 This region plays a crucial role in the interaction of a Syn with lipids and biological membranes.
369 Binding to membranes is mediated through the repeated KTKEGV motif that is essential for the
370 formation of an amphipathic α -helical structure needed for the interactions with membranes,

371 which ultimately affect several structural and functional aspects of aSyn in cells. For example,
372 aSyn exists, under normal conditions, in a dynamic equilibrium between its cytosolic soluble
373 disordered form and helically structured membrane-bound conformations (59, 60). Interestingly,
374 most PD known mutations are present in the N-terminal domain region of aSyn leading to
375 conformational alterations affecting its helical propensity, and therefore its preferential binding to
376 membranes versus its solubility in the cytosol, and ultimately functional and pathological
377 properties (47, 61). The K58N mutation is also located in the N-terminal region and, more
378 importantly, within the KTKEGV sequence. Lysines (K) are charged residues that play important
379 role in the formation of amphipathic α -helices by establishing electrostatic interactions with
380 negatively charged heads of the lipids in the membranes. The replacements of the charged residue
381 (K) within the KTKEGV sequence with uncharged residue asparagine (N) is expected to disrupt
382 α -helix formation and electrostatic interactions with membranes (62). Furthermore, asparagine
383 residues tend to occur in bends, turns and random coils. Consistently, our NMR data showed a
384 local effect for the K58N mutation that was found mainly around the mutation site, which
385 decrease the α -helical content of residues A53-N65. Simulation data were complementary to
386 NMR findings, further supporting the idea that the K58N mutation disrupts the helical propensity
387 of aSyn around the mutation site. The mutation-induced alterations in conformational dynamics
388 are expected therefore to influence several functional properties for aSyn including its interactions
389 with membranes. Despite this, the extent to which each PD-associated mutation alters membrane
390 binding can differ from one mutation to another mutation, and can be influenced by other factors
391 including the lipid composition and the curvature of those membranes. Among PD mutations,
392 A30P is known to exhibit defective binding to membranes due to its decreased helical propensity
393 (63, 64). In the current study, we observed that the α -helical propensity for K58N is reduced in
394 the presence of liposomes when compared to WT aSyn, consistent with a lower affinity of K58N
395 to lipids.

396 A central pathological hallmark of various synucleinopathies is misfolding and aggregation of
397 aSyn into insoluble and fibrillar protein deposits. Furthermore, different fibrils strains have been
398 observed in certain synucleinopathies. Therefore, we investigated the impact of the K58N
399 mutation on aSyn assembly. Importantly, the mutation occurs in a residue that is very close the
400 central hydrophobic domain which plays a crucial role in the aggregation of aSyn. Furthermore,
401 the local effects induced by this mutation were not limited to the immediate proximity of the
402 mutation site but also residues further away, including some in the beginning of the central
403 hydrophobic domain. According to different aggregation prediction algorithms, it is expected that
404 K58N mutant aSyn exhibits higher aggregation propensity. Interestingly, this is consistent with
405 our experimental in vitro aggregation assays that showed increased ThT binding and different
406 aggregation kinetics when compared to WT aSyn. It is possible that the positively charged K at 58
407 position protects against aggregation, and that this effect is lost once it is mutated to a neutral N
408 residue. This is consistent with data from studies of the H50Q mutation, as both substitutions have
409 similar charge effects. Histidine at position 50 carries a partial positive charge at neutral pH, and
410 it is substituted by a neutral Q leading to increased aggregation tendency in vitro (65, 66).

411 The observed changes may also reflect differences in the structural characteristics of the fibrils
412 between WT and K58N aSyn. The findings from cryo-EM data revealed that the K58N mutation
413 preferentially results in 2PF fibrils with a similar protofilament fold than WT fibrils, suggesting
414 that the mutation stabilizes the WT inter-protofilament interface. One possibility is that K58
415 modulates the ability of the adjacent interface-stabilizing residue (E57) to interact in cis or trans.
416 In WT, K58 may form a salt bridge in cis with E57, which could destabilize the inter-
417 protofilament interface and thereby favour 1PF structures. In contrast, the K58N mutation may
418 prevent this interaction due to the altered charge properties, thereby promoting trans interactions
419 with K45 of an adjacent protofilament and thus favoring in 2PF fibrils. Interestingly, the effects of
420 the K58N mutation are opposite to those we recently reported for the G14R mutation (24), which

421 strongly favors 1PF forms. Altogether, these results indicate that the main effect of these
422 mutations in fibril architecture is the modulation of the WT conformational landscape, favoring
423 either 1PF (G14R) or 2PF (K58N) forms.

424 In cells, K58N aSyn formed fewer inclusions when compared to WT aSyn and, overall these
425 inclusions were smaller. These data are not surprising as some aSyn mutations previously studied
426 showed, for example, attenuated aSyn aggregation in vitro while exhibiting increased formation
427 of cellular inclusions (24, 47). The findings using the yeast model revealed a more diffuse
428 cytoplasmic distribution, further demonstrating the importance of employing diverse experimental
429 models when evaluating the effects of mutations in the behaviour of aSyn, as this will likely
430 uncover different properties of the protein.

431 The process of aSyn phase separation, leading to the formation of condensates (67, 68), is
432 considered dynamic under physiological conditions, but it has been shown that aSyn phase
433 separation, under certain pathological states, can result in the formation of precursors or seeds that
434 transform into solid, insoluble pathological aggregates (69–71). More recently, it has been shown
435 that aSyn phase separation and condensate formation is regulated by VAMP2 (48, 72), and that
436 this regulatory mechanism may rely on the binding of aSyn to lipid membranes (48). In this assay,
437 the A30P aSyn mutant, which is typically known for its defective lipid-binding properties (62,
438 73–75) and increased cytoplasmic localization (50, 76), failed to form condensates in cells.
439 Interestingly, several assays conducted here revealed that the K58N mutant exhibits disrupted
440 binding to membranes and increased cytosolic distribution, similarly to what was observed with
441 A30P.

442 The phosphorylation of aSyn at serine 129 (pS129), previously recognized as pathological
443 hallmark (33), is increasingly considered to also play a physiological role (34, 77). This
444 phosphorylation is a dynamic and reversible neuronal activity-dependent process that increases
445 when neurons are stimulated, and is reversed when neuronal activity is reduced (34). In our study,

446 we observed similar patterns of activity-dependent pS129 for both WT and K58N aSyn, in
447 agreement with previous findings for some PD-associated mutations (24, 49). These findings are
448 consistent with different pathological effects by different mutations, and is consistent with a more
449 benign disease course in the affected patient. Nevertheless, our study points to the importance of
450 assessing the dynamic reversibility of S129 phosphorylation, as this sheds light into the molecular
451 effects of aSyn mutations.

452 In conclusion, we report the identification of a novel heterozygous *SNCA* mutation, encoding for
453 K58N aSyn, that is characterized clinically by causing early onset, and a benign course of PD that
454 showed good response to DBS. The mutant protein was found to exhibit unique molecular and
455 functional properties, such as reduced helical propensity, impaired lipid binding, increased
456 solubility, and reduced condensation and inclusion formation in cells. Ultimately, our findings
457 advance our understanding of the biology and pathobiology of aSyn, and provide new insight into
458 the molecular mechanisms underlying PD and other synucleinopathies.

459

460 **Materials and methods**

461 The patient was evaluated by neurologists specialized in movement disorders at the tertiary
462 movement disorder center Paracelsus Elena-Klinik, Kassel, Germany. Repeated general and
463 neurologic examinations included assessment of motor-symptoms by UPDRS, cognition by
464 MMST, standardized levodopa challenge as described previously. Written informed consent was
465 given by the patient to participate in a genetic study in cooperation with the Institute of Human
466 Genetics, Technical University Munich, Germany. The study was approved by local ethic
467 committees. Additional consent to confirm the genetic finding at the Institute of Human Genetics,
468 University Clinic Göttingen, Germany was provided. Deep brain surgery (DBS) was performed at
469 the Clinic of Neurosurgery, University Medical Center Göttingen, Germany.

470

471 **Genetic testing**

472 Whole-exome sequencing (WES) was performed at the Institute of Human Genetics at the
473 Technical University of Munich, Germany. Genomic DNA was extracted from peripheral blood
474 according to standard protocols. In-solution enrichment of targeted regions was accomplished
475 using the Sure Select Human All Exon Kit (Agilent 60mb V6) and followed by paired-end
476 sequencing of 100 base pair (bp) long reads with the Illumina NovaSeq6000 system (Illumina,
477 San Diego, California). Average exome coverage was 102x, with 97% of the target regions being
478 covered at least 20x. The whole *SNCA* region was covered >20x (average depth 80x). The
479 mutation was confirmed in an independent blood sample by Sanger sequencing by the Human
480 genetics Department at the University Medical Center Göttingen.

481

482 **Expression and purification of recombinant WT and K58N aSyn**

483 The K58N mutation was incorporated into the bacterial plasmid encoding aSyn using through
484 site-directed mutagenesis (QuikChange II, Agilent), and Sanger sequencing was used to validate
485 the presence of the mutation. The production of recombinant proteins was performed in
486 BL21(DE3) *E. coli* cells that were transformed with pET21A vectors encoding either WT or
487 G14R aSyn, following established protocols (78). After extracting proteins from bacterial pellets,
488 they were purified through sequential anion-exchange and size-exclusion chromatography (SEC)
489 for use in aggregation assays, nuclear magnetic resonance (NMR) analysis, and lipid binding
490 experiments. The purified proteins were concentrated in PBS buffer (pH 7.4), sterile-filtered, and
491 stored at -80°C until further use. For NMR studies, the SEC buffer was replaced with 100 mM
492 NaCl, 50 mM HEPES, pH 7.4. Determination of proteins concentration was done by measuring
493 absorbance at 280 nm, applying an extinction coefficient of 5,960 M⁻¹cm⁻¹.

494

495 **Liposome preparation**

496 5 mg of 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE):1,2-dioleoyl-sn-glycero-3-
497 phospho-L-serine (DOPS):1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) 5:3:2 w/w (Avanti
498 Polar Lipids) were resuspended in 0.8 mL methanol:chloroform 1:1, evaporated under a nitrogen
499 stream, lyophilized o/n and resuspended in 0.52 mL of HEPES buffer (50 mM HEPES, 100 mM
500 NaCl, pH 7.4, 0.02% NaN₃). The resulting turbid sample was sonicated until transparency (15
501 minutes, 10'' on, 20'' off).

502

503 **Circular dichroism (CD) spectroscopy**

504 Individual WT and K58N α Syn-to-lipid ratios were pipetted (ratio: 1:10, 1:20, 1:40, 1:100 and
505 1:200) at a protein concentration of 50 μ M and the respective lipid concentrations from a 12.5
506 mM liposome stock in HEPES buffer (50 mM HEPES, 100 mM NaCl, pH 7.4, 0.02% NaN₃) to a
507 total volume of 12 μ L. For CD measurement the sample was diluted in 48 μ L deionized water and
508 transferred to a 0.02 cm pathlength FireflySci cuvette for a final protein concentration of 10 μ M.
509 CD data were collected from 190 to 260 nm by using a Chirascan-plus qCD spectrometer
510 (Applied Photophysics, Randalls Rd, Leatherhead, UK) at 20 °C, 1.5 time-per-point (s) in 1 nm
511 steps. The datasets were averaged from three repeats. All spectra were baseline corrected against
512 buffer in deionized water and smoothed (window size: 8).

513

514 **NMR spectroscopy**

515 NMR experiments were measured on a Bruker 900 MHz spectrometer equipped with a 5 \square mm
516 triple-resonance, pulsed-field z-gradient cryoprobe. Two-dimensional ¹H,¹⁵N and ¹H,¹³C
517 heteronuclear single quantum coherence (HSQC) and ¹H,¹H total correlation spectroscopy
518 (TOCSY) experiments were acquired for monomer characterization at 15 °C. All experiments
519 were performed in HEPES buffer (50 mM HEPES, 100 mM NaCl, pH 7.4, 0.02% NaN₃) with 5
520 % (v/v) D₂O. Spectra were processed with TopSpin 3.6.1 (Bruker) and analyzed using Sparky
521 3.115 (T. D. Goddard and D. G. Kneller, SPARKY 3, University of California, San Francisco).

522 The combined HN/N chemical shift perturbation was calculated according to $\sqrt{((\delta\text{HN})^2 +$
523 $(\delta\text{N}/10)^2)/2}^{1/2}$. Secondary structure was calculated subjecting the experimental HA, CA, HN and
524 N chemical shifts to TALOS-N (79).

525

526 **Molecular dynamics simulations**

527 Starting structures of the α Syn WT and K58N peptides (residues 51-65) were built in the PyMOL
528 Molecular Graphics System (Version 1.8.4.0, Schrödinger, LLC). Initially, the peptides were
529 equilibrated in a water box with 50,000 steps of energy minimization. To further equilibrate the
530 system, 100 ps each of volume (NVT) and pressure (NPT) equilibration were performed without
531 position restraints. The MD simulations were carried out in GROMACS (version 2018.3) using the
532 AMBER99SB-ILDN force field and the TIP3P water model at a temperature of 300 K, 1 bar of
533 pressure and with a coupling time (ζ T) of 0.1 ps. The peptides were solvated in water with 150
534 mM NaCl, ensuring overall charge neutrality. The particle mesh Ewald algorithm was used for
535 calculation of the electrostatic term, with a radius of 16 Å for the grid-spacing and Fast Fourier
536 Transform. The cut-off algorithm was applied for the non-coulombic potential with a radius of 10
537 Å. The LINCS algorithm was used to contain bonds and angles. MD simulations were performed
538 during 100 ns in 2 fs steps and saving the coordinates of the system every 10 ps. The α -helical
539 content over the simulation trajectory was analyzed using the PyMOL Molecular Graphics
540 System. Error bars were calculated from the results of 40 peptides (5 peptides in the water box of
541 8 independent simulations).

542

543 **In vitro thioflavin T fluorescence-based aggregation assays**

544 For the ThT aggregation kinetics assay setup, lyophilized protein was reconstituted in sterile
545 filtered bidistilled water. To get rid of any potential aggregates in protein solutions, samples were
546 first centrifuged at 14,000 rpm for 5 minutes in 100 kDa MWCO filter tubes (Sigma-Aldrich,

547 MO, USA) to collect the filtrate containing monomeric aSyn. Protein concentration was
548 determined on an LVis Plate (BMG Labtech; Ortenberg, Germany) using a CLARIOstar Plus
549 plate reader (BMG Labtech; Ortenberg, Germany) employing the previously mentioned extinction
550 coefficient for aSyn. Prior to initiating the assay, a master mix of 0.5 mg/mL WT or K58N aSyn
551 was prepared in 150 mM NaCl, 10 mM PBS (pH 7.4), 1 mM EDTA, 0.002% SDS, and 25 μ M
552 ThT, with 100 μ L added into each well in quadruplicate per condition, in addition to the use of
553 protein-free master mix as a blank. The aggregation assay was conducted using CLARIOstar Plus
554 plate reader (BMG Labtech, Ortenberg, Germany) and Costar black, clear-bottom 96-well half-
555 area plates with preloading a single 1-mm glass bead to each well. Plates were sealed with
556 microplate tape and transferred to the reader, with the following settings: orbital shaking (60
557 seconds on, 30 seconds off) at 400 rpm, 37 °C, in 3.66 min cycles for a total of 1,000 cycles. ThT
558 fluorescence was measured at the end of each cycle with bottom optics, excitation at 450 ± 10 nm,
559 and emission at 480 ± 10 nm. Aggregation curves were then blank-corrected and normalized to
560 the maximum fluorescence for each run.

561

562 **Cryo-EM imaging and analysis of WT and K58N fibrils**

563 Cryo-EM sample Preparation

564 Copper 200 mesh R2/1 Quantifoil grids were plasma cleaned for 45 seconds at medium power
565 using a Harrick Plasma PDC-32G-2 plasma cleaner and then mounted on a Vitrobot Mark IV
566 (Thermo Fisher). Alpha-synuclein fibrils, prepared at a concentration of 0.5 mg/mL in 30 mM
567 Tris-HCl buffer at pH 7.5, were sonicated in a waterbath sonicator for 10 minutes on medium
568 settings with a 0.5s ON/OFF interval. Shortly thereafter a 3 mL aliquot of the fibrils was applied
569 to the grid. Blotting was performed with a blot force of 7 for 5 seconds. During the freezing
570 process, the Vitrobot chamber was kept at 10°C with 100% humidity.

571 Data Collection

572 Cryo-EM datasets were acquired using a Titan Krios electron microscope (Thermo Fisher)
573 equipped with a Falcon4i detector operated in counting mode. For this study, we collected a
574 dataset for the K58N aSyn mutant under the described conditions and used a previously acquired
575 WT dataset, originally collected as part of the G14R study, as a control. Both datasets were
576 collected at a nominal magnification of 130,000x, yielding a pixel size of 0.92 Å. The K58N
577 dataset consisted of 5,813 movies, while the WT dataset comprised 4,092 movies. The defocus
578 range for both datasets was maintained between -1.2 and -2.4 µm. A total electron dose of 40 e⁻
579 /Å² was applied, with exposures of 6.59 e⁻/Å²s for the WT dataset and 6.61 e⁻/Å²s for the K58N
580 dataset. An energy filter with a 15 eV slit width was employed during data collection.

581 Data Processing

582 The raw EER movies were fractionated, aligned, and summed using MotionCor2 with a dose per
583 frame of 1 e⁻/Å². Contrast transfer function (CTF) parameters were estimated using CTFFIND4.
584 To select segments for both the WT and K58N datasets, a crYOLO model was employed, which
585 had been trained on previously grown recombinant aSyn filaments. For this, fibrils from about 50
586 micrographs of a previous WT aSyn dataset were manually picked in RELION-4, and the
587 coordinates were exported to train a picking model in crYOLO. This model was subsequently
588 used to automatically pick fibrils across all micrographs. The filament coordinates were imported
589 into RELION and used to extract helical segments with an inter-box spacing of approximately 15
590 Å, corresponding to three asymmetric units per segment. Segments were first extracted with a box
591 size of 768 pixels, binned three times to a final box size of 256 pixels, and then subjected to 2D
592 classification. After excluding picking artifacts, such as carbon edges, the remaining particles
593 were used to extract unbinned segments with a box size of 384 pixels and a pixel size of 0.92
594 Å/px. Another round of 2D classification was performed, and only the classes showing beta-
595 sheets were selected for further analysis. In case of 1 protofilament (PF) classes for the K58N
596 dataset, no further classifications were carried out since class averages did not show betasheets.

597 Segments of the selected classes underwent 3D classifications, during which helical parameters
598 were systematically scanned as the crossover distance was not visible in the micrographs and the
599 twist could not be determined directly. Multiple 3D classifications were carried out with a fixed
500 helical rise of 4.75 Å and a twist ranging from -0.5° to -1.7° in roughly 0.05° increments. A
501 featureless cylinder was used as the initial model. Classes showing distinct polypeptide signals
502 were utilized as initial models for subsequent 3D refinements that were performed using a
503 sampling interval of 1.8° and a T-value of 15 to 30. Postprocessed models were then used for
504 CTF refinements and final 3D refinements to optimize resolution and model quality.

505

506 **aSyn aggregation studies in cells**

507 Cell culture

508 Human neuroglioma cells (H4) were maintained in Opti-MEM I Reduced Serum Medium (Life
509 Technologies- Gibco, Carlsbad CA, USA) supplemented with 10% Fetal Bovine Serum Gold
510 (FBS) (PAA, Cölbe, Germany) and 1% Penicillin-Streptomycin (PAN, Aidenbach, Germany).
511 The cells were grown at 37°C in an atmosphere of 5% CO₂.

512 Cell Transfection

513 Twenty-four hours prior to transfection, approximately 80000 H4 cells were plated per well in a
514 12-well plate (Costar, Corning, New York, USA). Six hours prior to transfection, the medium was
515 replaced with a fresh one. Transfection protocol using Fugene methodology was carried out as
516 described by the manufacturer. Briefly, ratio of 1 (equal amounts of the plasmids encoding SynT
517 Wild Type Kozak or SynT K58N Kozak with/without Synphilin-1-V5) :3 (Fugene solution) mix
518 was prepared in Optimem medium without adds. The mix was incubated for 20 min and added
519 dropwise to the cells while the plate was gently rocked.

520 Immunocytochemistry

521 Forty hours after transfection, the medium was removed, the cells were washed with PBS and
522 fixed with 4% paraformaldehyde (PFA) for 30 minutes at room temperature (RT). Cell
523 permeabilization with 0.1% Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA) for 20 minutes at
524 RT was performed, followed by blocking in 3% Bovine serum albumin (Nzytech, Lisbon,
525 Portugal) in PBS 1x for 1 hour. Afterwards, cells were incubated with primary antibody mouse
526 anti-ASYN (1:1000, BD Transduction Laboratory, New Jersey, USA) overnight and secondary
527 antibody Alexa Fluor 488 goat anti-mouse (Life Technologies- Invitrogen, Carlsbad, CA, USA)
528 for 2 hours at RT. Finally, cells were stained with DAPI (Carl Roth, Karlsruhe, Germany) (1:5000
529 in PBS 1x) for 10 minutes, and the coverslips mounted in SuperFrost® Microscope Slides treated
530 with Mowiol (Calbiochem, San Diego, CA) dried and stored at room temperature until further
531 visualization and analysis. Images were acquired using a confocal point-scanning microscope
532 (Zeiss LSM 900 with Airyscan, Carl Zeiss, Jena, Germany). For each condition, 50 images of the
533 10 slices Z-Stack were taken using the 63x objective (Objective Plan-Apochromat 63x/1.4 Oil
534 DIC M27) and specific definitions for each staining in the ZEN Software (Carl Zeiss, Jena,
535 Germany). To quantify the number of aggregates and the size of the aggregates (area of the
536 inclusions) inside the cells, the aSyn channel was selected and the images were thresholded. The
537 images were then analysed using the Analyse particle plugin from Fiji open-source software (80).

538

539 **Solubility and dynamic pS129 reversibility experiments**

540 Plasmids and lentivirus production: synthetic cDNA sequences encoding WT or K58N aSyn were
541 digested at the SpeI/NotI enzymes restriction sites and then ligated into pLVX-EF1a-IRES
542 ZsGreen1 vector (TaKaRa) for their expression, driven by the EF1a promoter. Lentiviral
543 packaging was carried out in 293-T cells as previously described (34). Briefly, 293-T cells were
544 transfected with plasmids encoding WT or K58N aSyn along with the packaging plasmids
545 pMD2.G and psPAX2 (Addgene #12259 and #12260). After transfection, the viral particles from

546 the culture supernatant were collected, and subjected to ultracentrifugation at 100,000g for
547 obtaining purified/concentrated viral particles. The purified viral pellet then reconstituted in
548 neurobasal medium containing B-27 and Glutamax (Gibco), resulting in a yield around 2.5×10^6
549 viral particles per μL . To investigate the impact of K58N mutation on phosphorylation status of
550 aSyn at S129, we cultured primary cortical neurons from E18 pregnant SNCA knockout
551 (SNCA $^{-/-}$) rats on 24-well plates previously coated with poly-d-lysine, and induced the
552 expression of human WT or K58N proteins by lentiviral transduction at DIV5 as described (49).
553 To assess the solubility of aSyn of K58N vs. WT aSyn, we performed sequential protein
554 extraction to isolate cytosol (C) vs. membrane (M) protein fractions using the on-plate extraction
555 technique as previously described (81). For the experiments assessing dynamic reversibility of
556 pS129, cortical cultures were treated at DIV17-21 with vehicle (DMSO), 20 μM picrotoxin
557 (PTX), 1 μM tetrodotoxin (TTX), or combination of both PTX and TTX. Following treatment for
558 2h or 4h intervals, cell lysis and immunoblotting was conducted to measure the levels of total and
559 pS129 aSyn as previously described (34, 49). For this study, at least three independent
560 experiments were carried out on different days, with a total of 10-16 biological replicates. Data
561 presented in Fig. 6 B, D, and I-L are statistically analyzed by an unpaired *t*-test with Welch's
562 correction, while data in F-G were analyzed by Brown-Forsythe and Welch ANOVA with
563 Dunnett's T3 *post hoc* test for multiple comparisons. Data in Fig. 6 H were analyzed by a two-
564 way ANOVA with Šídák's multiple comparisons test. Please note: In the experiments assessing
565 the solubility and dynamic reversibility of pS129, both G14R (24) and G58N mutants were
566 characterized in parallel. Consequently, the data points for WT-aSyn are identical across both sets
567 of experiments (Fig. 6 D, F, H, I, J, K, and L).

568

569 **aSyn expression and purification for phase separation studies**

570 Recombinant wild-type and K58N human full-length aSyn was expressed in BL21(DE3)
571 competent *Escherichia coli* (C2527, NEB, Ipswich, US) using vector pET28a (Addgene
572 #178032). Bacteria were cultured in LB media supplemented with 50 µg/mL kanamycin (37 °C,
573 constant shaking at 250 rpm). Expression was induced at an OD₆₀₀ of 0.8 using 1mM isopropyl
574 β-D-1-thiogalactopyranoside (IPTG) and cultured overnight at 25 °C. Cell pellets were harvested
575 by centrifugation at 4000 × g for 30 minutes (AVANTI J-26, Beckman Coulter, USA). aSyn was
576 purified using a protocol previously described (2). Briefly, the cell pellet was resuspended in lysis
577 buffer (10 mM Tris, 1 mM EDTA, Roche cOmplete EDTA free protease inhibitor cocktail, pH 8).
578 The cells were disrupted using a cell disruptor (Constant Systems, Daventry, UK) and were
579 ultracentrifuged at 4 °C, 186,000 × g for 20 minutes (Ti-45 rotor, Optima XPN 90, Beckman
580 Coulter, USA). The supernatant was collected and heated for 20 minutes at 70 °C to precipitate
581 heat-sensitive proteins, followed by ultracentrifugation as above. Streptomycin sulfate (5711,
582 EMD Millipore, Darmstadt, Germany) was added at a final concentration of 10 mg/mL to the
583 supernatant and continuously stirred at 4 °C for 15 minutes to precipitate DNA, followed by
584 ultracentrifugation as above. Ammonium sulfate (434380010, Thermo Scientific) was added at a
585 final concentration of 360 mg/mL to the supernatant and continuously stirred at 4 °C for 30
586 minutes to precipitate the protein. The precipitated protein was then centrifuged at 500 × g for 15
587 min, dissolved in 25 mM Tris, pH 7.7, and dialyzed overnight against the same buffer to remove
588 salts. The protein was purified using ion exchange on a HiTrap™ HP 5mL anion exchange
589 column (17115401, Cytiva, Sweden) using gradient elution with 0-1M NaCl in 25 mM Tris, pH
590 7.7. The collected protein fractions were run on SDS-PAGE and pooled fractions were further
591 purified using size-exclusion chromatography on a HiLoad™ 16/600 Superdex™ 75 pg
592 column (28989333, Cytiva, Sweden). The fractions were collected, and their purity was
593 confirmed using SDS-PAGE analysis. Protein concentrations were determined by measuring
594 absorbance at 280 nm using an extinction coefficient of 5,600 M⁻¹ cm⁻¹. The monomeric protein

595 was frozen in liquid nitrogen and stored in 25 mM HEPES buffer pH 7.4 at -70 °C. pET28a
596 Cdk2ap1CAN was a gift from Lin He (Addgene plasmid # 178032;
597 <http://n2t.net/addgene:178032>; RRID:Addgene 178032) (3).

598

599 **aSyn labelling**

700 Labelling of aSyn was performed in bicarbonate buffer (C3041, Sigma) at pH 8 using NHS-ester
701 active fluorescent dye AlexaFluor 488 5-SDP ester (A30052, Invitrogen Thermo Fisher). Excess-
702 free dye was removed by buffer exchange using PD10 desalting columns (IP-0107-Z050.0-001,
703 emp BIOTECH, Generon). Labelled protein concentrations were estimated using the molar
704 extinction coefficient $\epsilon_{494\text{ nm}} = 72,000 \text{ M}^{-1} \text{ cm}^{-1}$.

705

706 **aSyn phase separation assays**

707 All aSyn phase separation assays were performed in 25 mM HEPES, pH 7.4 unless mentioned
708 otherwise. Phase separation was induced by mixing aSyn and PEG-8000 (BP223, Fisher
709 Bioreagent) in the presence of calcium (21108, Sigma) as indicated. Images for phase-separated
710 samples were acquired on an LSM780 confocal microscope (Zeiss, Oberkochen, Germany) using
711 a 63x oil immersion objective. Zen 2.3 (black edition) and Zen 2.6 (blue edition) were used for
712 data collection and image export. Images were taken at the indicated aSyn concentration, where
713 aSyn was supplemented with 1% Alexa 488 labelled aSyn. For turbidity measurements phase
714 separation samples were set up as described above using indicated concentrations of aSyn and
715 PEG-8000 in the presence of calcium (21108, Sigma). The turbidity of the samples was measured
716 at 350 nm, 25 °C using 96-well Greiner optical bottom plates on a CLARIOstar plate reader
717 (BMG LABTECH, Ortenberg, Germany) under quiescent conditions. CLARIOStar 5.01 was used
718 for data acquisition. A sample volume of 100 μL was used, and readings were taken within 5

719 minutes of sample preparation. Raw turbidity data are plotted with background subtraction using
720 GraphPad Prism 9.3.1. Data were obtained from four independent repeats.

721

722 **Plasmids**

723 Wild-type human full-length SNCA and VAMP2, encoding aSyn and VAMP2, were cloned from
724 cDNA obtained from human neuroblastoma cells (SH-SY5Y) and inserted into the pEYFP-N1
725 and pMD2.G vector (Addgene #96808, #12259) with a C-terminal YFP and Flag-tag,
726 respectively. aSyn K58N was generated using KLD substitution (M0554S, NEB, Ipswich, US).
727 All sequences were verified by sequencing. 5HT6-YFP-Inpp5e was a gift from T. Inoue
728 (Addgene plasmid 96808; RRID: Addgene_96808)128. pMD2.G was a gift from D.Trono
729 (Addgene plasmid 12259; RRID: Addgene_12259).

730

731 **Cell culture and transfection**

732 HeLa cells were obtained from the European Collection of Cell Cultures (ECACC 93021013) and
733 grown in Dulbecco's modified Eagle's Medium (DMEM) high glucose (31966-021, Gibco)
734 supplemented with 10% fetal bovine serum (FBS, F7524, Sigma) and 1% Penicillin/Streptomycin
735 (P0781, Sigma). Cells were grown at 37 °C in a humidified incubator with 5% CO₂. Cells were
736 tested for mycoplasma contamination using MycoStrip™ (IvivoGen, Toulouse, France). Cells
737 were plated at 20,000 cells/well in 8-well ibidi dishes (80807, ibidi, Gräfelfing, Germany) for
738 confocal imaging or in 48-well plates (Cellstar, 677 180, Greiner bio-one) for incuCyte
739 experiments. Cells were transfected the following day using Fugene HD Transfection reagent
740 according to the manufacturer's protocol (E2311, Promega). Briefly, per reaction 12.5 µL
741 OptiMEM (31985-062, Gibco) were set up in 1.5 mL sterile Eppendorf tubes. A total of 250 ng of
742 DNA and 0.75 µL of Fugene reagent were added and incubated for 15 min at room temperature.

743 The transfection mix was added to the cells for 1 min and then topped up with 300 μ L complete
744 media. Cells were imaged the next day.

745

746 **Confocal microscopy and IncuCyte**

747 Live cell confocal imaging was performed on an LSM780 microscope (Zeiss, Oberkochen,
748 Germany) using a 63x oil immersion objective. YFP fluorescence was excited with the 514 laser
749 at 2% laser power. Zen 2.3 (black edition) and Zen 2.6 (blue edition) were used for data collection
750 and image export. For quantitative evaluation of condensate formation cells were imaged with the
751 IncuCyte S3 (Essen BioScience, Newark, UK). Phase brightfield and green fluorescence images
752 were taken using a 20x objective at a 4-hour interval at 200 ms exposure, condensate formation
753 (% of cells showing condensate formation) was evaluated 16 hours after transfection. IncuCyte
754 2021A was used for data analysis. At least three biological repeats with three technical repeats
755 each were analysed blinded to the investigator.

756

757 **Quantification and statistical analysis**

758 Data analysis and statistical analysis was performed using Excel 2016 and GraphPad Prism 9.3.1.
759 All data are represented as mean \pm standard error (SD) if not indicated otherwise. Statistical
760 analysis was carried out using unpaired two-tailed t-test. Statistical parameters are reported in the
761 Fig.s and the corresponding Fig. Legends. Exact p-values are shown. Data distribution was
762 assumed to be normal but this was not formally tested. No statistical methods were used to pre-
763 determine sample sizes but our sample sizes are similar to those reported in previous publications
764 (4–6). Samples were randomly allocated into experimental groups. Data collection and analysis
765 have been performed blinded when indicated. Data were included if the control (wild-type)
766 showed appropriate condensate formation.

767

768 **Yeast Plasmids**

769 The aSyn-K58N variant was constructed by site-directed mutagenesis using the QuickChange II
770 Site-Directed Mutagenesis Kit (Agilent Technologies, SC, USA), in the plasmid backbone
771 p426GPD encoding the WT aSyn-GFP, following the manufacturer's instructions. We also
772 constructed a plasmid expressing only GFP as a control, by introducing the GFP coding sequence
773 as a SpeI-XhoI digested PCR product in the p426GPD backbone. All constructs were confirmed
774 by DNA sequencing.

775

776 **Yeast cell growth conditions, viability assay and fluorescence microscopy**

777 The *Saccharomyces cerevisiae* yeast strain BY4741 (MATa his3 Δ 1 leu2 Δ 0 met15 Δ 0 ura3 Δ 0) was
778 transformed with GFP, WT aSyn and K58N plasmids by standard lithium acetate method. All
779 strains were grown overnight at 30 °C 180 rpm in yeast minimal synthetic defined (SD) medium
780 (Takara Bio), supplemented with a drop-out mix (Takara Bio) lacking the amino acid uracil (SD-
781 URA) for transformant selection, at a volume/medium ratio of 5:1.

782 The assessment of cellular viability was achieved by spotting assay. Here, cultures grown to mid-
783 log phase were standardized to equal cellular densities, serially diluted 10-fold starting with an
784 OD_{600nm} of 1 and spotted on SD-URA agar plates. Following 3 days incubation at 30 °C the
785 plates were photographed.

786 aSyn cellular localization was evaluated by fluorescent microscopy. Images were attained with an
787 epifluorescence microscope Zeiss Axio Observer equipped with a 100x oil objective lens.

788

789

790

791

792

793

794

795

796

797

798

799

300

301

302

303

304

305

306 **Abbreviations**

307	aSyn	Alpha-synuclein
308	EOPD	Early onset PD
309	LBD	Lewy body dementia
310	MSA	Multiple system atrophy
311	PD	Parkinson's disease
312	SNCA	Alpha-synuclein gene

313

314 **Acknowledgements**

315 We thank Dr. Ellen Gerhardt for assistance with site-directed mutagenesis in the aSyn-encoding
316 plasmids.

317

318 Mohammed Al-Azzani^{1†}, Sandrina Weber^{2†}, Nagendran Ramalingam³, Maria Ramón¹, Liana
319 Shvachiy¹, Gonçalo Mestre¹, Michael Zech^{4,5,6}, Kevin Sicking^{7,8}, Alain Ibáñez de Opakua⁹,
320 Vidyashree Jayanthi³, Leslie Amaral^{1,10}, Aishwarya Agarwal¹¹, Aswathy Chandran¹¹, Susana R.
321 Chaves¹⁰, Juliane Winkelmann^{4,5,12,13}, Claudia Trenkwalder^{14,15}, Maike Schwager¹⁶, Silke Pauli¹⁶,
322 Ulf Dettmer³, Claudio O. Fernández¹⁷, Janin Lautenschläger¹¹, Markus Zweckstetter^{9,18}, Ruben
323 Fernandez Busnadiego^{7,8,19,20}, Brit Mollenhauer^{2,15*}, and Tiago Fleming Outeiro^{1,9,21,22*}

324

325 **Author contributions**

326 TFO and BM contributed to the study conception and design. MAA, SB, NR, MR, LS, GM, MZ,
327 KS, AIO, VJ, LA, AA, and AC contributed to the acquisition of data.
328 MAA, SB, NR, KS, UF, JL, MZZ, CF, JW, CT, MS, SP, RFB, BM, and TFO analyzed and
329 interpreted the data.

330 MAA, SB, and TFO wrote the initial draft of the manuscript. All authors reviewed and revised the
331 manuscript.

332

333 **Funding**

334 T.F.O. is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research
335 Foundation) under Germany's Excellence Strategy, EXC 2067/1- 390729940, and by SFB1286
336 (B8). J.L. is supported by the Royal Society (Royal Society Dorothy Hodgkin Research
337 Fellowship, DHF/R1/201228), the Addenbrooke's Charitable Trust (Grant Award 900325), the
338 Leverhulme Trust (Research Project Grant, RPG-2022-257), as well as a Career Support Fund
339 from the University of Cambridge. L.S. was supported by the Foundation for Science and
340 Technology (FCT), SFRH/BD/143286/2019. N.R. and U.D. are supported by the National
341 Institutes of Health (grant numbers NS121826, NS099328, NS109209, NS122880, and
342 NS133979). M. Zweckstetter is supported by the Michael J. Fox foundation through MJFF-
343 022411. M.Zech acknowledges grant support by the European Joint Programme on Rare Diseases
344 (EJP RD Joint Transnational Call 2022), and the German Federal Ministry of Education and
345 Research (BMBF, Bonn, Germany), awarded to the project PreDYT (PREdictive biomarkers in
346 DYsTonia, 01GM2302), by the Federal Ministry of Education and Research (BMBF) and the
347 Free State of Bavaria under the Excellence Strategy of the Federal Government and the Länder, as
348 well as by the Technical University of Munich – Institute for Advanced Study. MZ's research is
349 supported by a "Schlüsselprojekt" grant from the Else Kröner-Fresenius-Stiftung
350 (2022_EKSE.185).

351 R.F.B. is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research
352 Foundation) under Germany's Excellence Strategy, EXC 2067/1- 390729940, and by SFB1286
353 (A12). Cryo-EM instrumentation at the University of Göttingen was jointly funded by the DFG
354 Major Research Instrumentation program (448415290) and the Ministry of Science and Culture of

355 the State of Lower Saxony. K.S. and R.F.-B. were funded by the joint efforts of The Michael J.
356 Fox Foundation for Parkinson's Research (MJFF) and the Aligning Science Across Parkinson's
357 (ASAP) initiative. MJFF administers the grant ASAP-000282 on behalf of ASAP and itself.

358

359 **Conflict of interests**

360 The authors declare that they have no competing interests to disclose related to the article.

361

362 **Data availability**

363 All data needed to evaluate the conclusions in the paper are present in the paper and/or the
364 Supplementary Materials.

365 The micrographs used for the single-particle analysis (SPA) of alpha-synuclein fibrils are
366 available in the EMPIAR database under accession code EMPIAR-12518.

367 The atomic model and cryo-EM density map for the wild-type (WT) alpha-synuclein fibril are
368 deposited in the Protein Data Bank (PDB) and Electron Microscopy Data Bank (EMDB) under
369 accession codes 9HGS and EMD-52165, respectively. The corresponding data for the K58N
370 mutant alpha-synuclein fibril are available under accession codes 9HXA (PDB) and EMD-52458
371 (EMDB).

372 A comprehensive Key Resource Table, detailing datasets, software, and protocols is available via
373 Zenodo at <https://zenodo.org/records/14730688>. Additionally, the entry includes an Excel file
374 with tabular data on the protofilament distribution of WT and K58N alpha-synuclein filaments,
375 XML files containing tabular data for the FSC graphs of each density map used to determine the
376 final resolution (generated with RELION 4.0), and two Python scripts for graphing the FSC XML
377 data.

378 The full single-particle analysis protocol describing the cryo-EM data processing strategy is
379 available at Protocols.io ([https://www.protocols.io/view/single-particle-analysis-of-synuclein-](https://www.protocols.io/view/single-particle-analysis-of-synuclein-fibrils-81wgbxozylpk/v1)
380 [fibrils-81wgbxozylpk/v1](https://www.protocols.io/view/single-particle-analysis-of-synuclein-fibrils-81wgbxozylpk/v1)).

381

382

383

384 **References**

- 385 1. M. Flores-Leon, T. F. Outeiro, More than meets the eye in Parkinson's disease and other
386 synucleinopathies: from proteinopathy to lipidopathy. *Acta Neuropathol* **146**, 369–385
387 (2023).
- 388 2. R. B. Postuma, D. Berg, M. Stern, W. Poewe, C. W. Olanow, W. Oertel, J. Obeso, K.
389 Marek, I. Litvan, A. E. Lang, G. Halliday, C. G. Goetz, T. Gasser, B. Dubois, P. Chan, B.
390 R. Bloem, C. H. Adler, G. Deuschl, MDS clinical diagnostic criteria for Parkinson's
391 disease. *Movement Disorders* **30**, 1591–1601 (2015).
- 392 3. M. H. Polymeropoulos, C. Lavedan, E. Leroy, S. E. Ide, A. Dehejia, A. Dutra, B. Pike, H.
393 Root, J. Rubenstein, R. Boyer, E. S. Stenroos, S. Chandrasekharappa, A. Athanassiadou, T.
394 Papapetropoulos, W. G. Johnson, A. M. Lazzarini, R. C. Duvoisin, G. Di Iorio, L. I. Golbe,
395 R. L. Nussbaum, Mutation in the α -synuclein gene identified in families with Parkinson's
396 disease. *Science (1979)* **276** (1997).
- 397 4. M. G. Spillantini, M. L. Schmidt, V. M. Y. Lee, J. Q. Trojanowski, R. Jakes, M. Goedert,
398 α -synuclein in Lewy bodies [8]. [Preprint] (1997). <https://doi.org/10.1038/42166>.
- 399 5. L. I. Golbe, G. Di Iorio, G. Sanges, A. M. Lazzarini, S. La Sala, V. Bonavita, R. C.
900 Duvoisin, Clinical genetic analysis of Parkinson's disease in the Contursi kindred. *Ann*
901 *Neurol* **40** (1996).

6. S. Appel-Cresswell, C. Vilarino-Guell, M. Encarnacion, H. Sherman, I. Yu, B. Shah, D. Weir, C. Thompson, C. Szu-Tu, J. Trinh, J. O. Aasly, A. Rajput, A. H. Rajput, A. Jon Stoessl, M. J. Farrer, Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. *Movement Disorders* **28** (2013).
7. M. Schweighauser, Y. Shi, A. Tarutani, F. Kametani, A. G. Murzin, B. Ghetti, T. Matsubara, T. Tomita, T. Ando, K. Hasegawa, S. Murayama, M. Yoshida, M. Hasegawa, S. H. W. Scheres, M. Goedert, Structures of α -synuclein filaments from multiple system atrophy. *Nature* **585** (2020).
8. Y. Yang, Y. Shi, M. Schweighauser, X. Zhang, A. Kotecha, A. G. Murzin, H. J. Garringer, P. W. Cullinane, Y. Saito, T. Foroud, T. T. Warner, K. Hasegawa, R. Vidal, S. Murayama, T. Revesz, B. Ghetti, M. Hasegawa, T. Lashley, S. H. W. Scheres, M. Goedert, Structures of α -synuclein filaments from human brains with Lewy pathology. *Nature* **610** (2022).
9. S. H. W. Scheres, B. Ryskeldi-Falcon, M. Goedert, Molecular pathology of neurodegenerative diseases by cryo-EM of amyloids. [Preprint] (2023). <https://doi.org/10.1038/s41586-023-06437-2>.
10. I. C. Brás, M. Xylaki, T. F. Outeiro, "Mechanisms of alpha-synuclein toxicity: An update and outlook" in *Progress in Brain Research* (2020)vol. 252.
11. D. J. Koss, D. Erskine, A. Porter, P. Palmoski, H. Menon, O. G. J. Todd, M. Leite, J. Attems, T. F. Outeiro, Nuclear alpha-synuclein is present in the human brain and is modified in dementia with Lewy bodies. *Acta Neuropathol Commun* **10** (2022).
12. K. Ezzat, A. Sturchio, A. J. Espay, Proteins Do Not Replicate, They Precipitate: Phase Transition and Loss of Function Toxicity in Amyloid Pathologies. [Preprint] (2022). <https://doi.org/10.3390/biology11040535>.

13. A. J. Espay, A. J. Lees, Loss of monomeric alpha-synuclein (synucleinopenia) and the origin of Parkinson's disease. [Preprint] (2024). <https://doi.org/10.1016/j.parkreldis.2024.106077>.
14. A. Westenberger, V. Skrahina, T. Usnich, C. Beetz, E.-J. Vollstedt, B.-H. Laabs, J. J. Paul, F. Curado, S. Skobalj, H. Gaber, M. Olmedillas, X. Bogdanovic, N. Ameziane, N. Schell, J. O. Aasly, M. Afshari, P. Agarwal, J. Aldred, F. Alonso-Frech, R. Anderson, R. Araújo, D. Arkadir, M. Avenali, M. Balal, S. Benizri, S. Bette, P. Bhatia, M. Bonello, P. Braganeto, S. Brauneis, F. E. C. Cardoso, F. Cavallieri, J. Classen, L. Cohen, D. Coletta, D. Crosiers, P. Cullufi, K. Dashtipour, M. Demirkiran, P. de Carvalho Aguiar, A. De Rosa, R. Djaldetti, O. Dogu, M. G. dos Santos Ghilardi, C. Eggers, B. Elibol, A. Ellenbogen, S. Ertan, G. Fabiani, B. H. Falkenburger, S. Farrow, T. Fay-Karmon, G. J. Ferencz, E. T. Fonoff, Y. D. Fragoso, G. Genç, A. Gorospe, F. Grandas, D. Gruber, M. Gudesblatt, T. Gurevich, J. Hagenah, H. A. Hanagasi, S. Hassin-Baer, R. A. Hauser, J. Hernández-Vara, B. Herting, V. K. Hinson, E. Hogg, M. T. Hu, E. Hummelgen, K. Hussey, J. Infante, S. H. Isaacson, S. Jauma, N. Koleva-Alazeh, G. Kuhlenbäumer, A. Kühn, I. Litvan, L. López-Manzanares, M. Luxmore, S. Manandhar, V. Marcaud, K. Markopoulou, C. Marras, M. McKenzie, M. Matarazzo, M. Merello, B. Mollenhauer, J. C. Morgan, S. Mullin, T. Musacchio, B. Myers, A. Negrotti, A. Nieves, Z. Nitsan, N. Oskooilar, Ö. Öztop-Çakmak, G. Pal, N. Pavese, A. Percesepe, T. Piccoli, C. Pinto de Souza, T. Prell, M. Pulera, J. Raw, K. Reetz, J. Reiner, D. Rosenberg, M. Ruiz-Lopez, J. Ruiz Martinez, E. Sammler, B. L. Santos-Lobato, R. Saunders-Pullman, I. Schlesinger, C. M. Schofield, A. F. Schumacher-Schuh, B. Scott, Á. Sesar, S. J. Shafer, R. Sheridan, M. Silverdale, R. Sophia, M. Spitz, P. Stathis, F. Stocchi, M. Tagliati, Y. F. Tai, A. Terwecoren, S. Thonke, L. Tönges, G. Toschi, V. Tumas, P. P. Urban, L. Vacca, W. Vandenberghe, E. M. Valente, F. Valzania, L. Vela-Desojo, C. Weill, D. Weise, J. Wojcieszek, M. Wolz, G. Yahalom, G. Yalcin-

- 050 Cakmakli, S. Zittel, Y. Zlotnik, K. K. Kandaswamy, A. Balck, H. Hanssen, M. Borsche, L.
051 M. Lange, I. Csoti, K. Lohmann, M. Kasten, N. Brüggemann, A. Rolfs, C. Klein, P. Bauer,
052 Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease
053 study. *Brain* **147**, 2652–2667 (2024).
- 054 15. L. Cook, J. Verbrugge, T.-H. Schwantes-An, J. Schulze, T. Foroud, A. Hall, K. S. Marder,
055 I. F. Mata, N. E. Mencacci, M. A. Nance, M. A. Schwarzschild, T. Simuni, S. Bressman,
056 A.-M. Wills, H. H. Fernandez, I. Litvan, K. E. Lyons, H. A. Shill, C. Singer, T. F. Tropea,
057 N. Vanegas Arroyave, J. Carbonell, R. Cruz Vicioso, L. Katus, J. F. Quinn, P. D. Hodges,
058 Y. Meng, S. P. Strom, C. Blauwendraat, K. Lohmann, C. Casaceli, S. C. Rao, K. Ghosh
059 Galvelis, A. Naito, J. C. Beck, R. N. Alcalay, Parkinson's disease variant detection and
060 disclosure: PD GENERation, a North American study. *Brain* **147**, 2668–2679 (2024).
- 061 16. K. Daida, S. Shimonaka, K. Shiba-Fukushima, J. Ogata, H. Yoshino, A. Okuzumi, T.
062 Hatano, Y. Motoi, T. Hirunagi, M. Katsuno, H. Shindou, M. Funayama, K. Nishioka, N.
063 Hattori, Y. Imai, α -Synuclein V15A Variant in Familial Parkinson's Disease Exhibits a
064 Weaker Lipid-Binding Property. *Movement Disorders* **37** (2022).
- 065 17. R. Krüger, W. Kuhn, T. Müller, D. Voitalla, M. Graeber, S. Kösel, H. Przuntek, J. T.
066 Epplen, L. Schöls, O. Riess, Ala30Pro mutation in the gene encoding α -synuclein in
067 Parkinson's disease. *Nat Genet* **18** (1998).
- 068 18. S. Lesage, M. Anheim, F. Letournel, L. Bousset, A. Honoré, N. Rozas, L. Pieri, K.
069 Madiona, A. Dürr, R. Melki, C. Verny, A. Brice, G51D α -synuclein mutation causes a
070 novel Parkinsonian-pyramidal syndrome. *Ann Neurol* **73** (2013).
- 071 19. H. Yoshino, M. Hirano, A. J. Stoessl, Y. Imamichi, A. Ikeda, Y. Li, M. Funayama, I.
072 Yamada, Y. Nakamura, V. Sossi, M. J. Farrer, K. Nishioka, N. Hattori, Homozygous
073 alpha-synuclein p.A53V in familial Parkinson's disease. *Neurobiol Aging* **57** (2017).

20. J. J. Zarranz, J. Alegre, J. C. Gómez-Esteban, E. Lezcano, R. Ros, I. Ampuero, L. Vidal, J. Hoenicka, O. Rodriguez, B. Atarés, V. Llorens, E. Gomez Tortosa, T. Del Ser, D. G. Muñoz, J. G. De Yebenes, The New Mutation, E46K, of α -Synuclein Causes Parkinson and Lewy Body Dementia. *Ann Neurol* **55** (2004).
21. C. Fevga, Y. Park, E. Lohmann, A. J. Kievit, G. J. Breedveld, F. Ferraro, L. de Boer, R. van Minkelen, H. Hanagasi, A. Boon, W. Wang, G. A. Petsko, Q. Q. Hoang, M. Emre, V. Bonifati, A new alpha-synuclein missense variant (Thr72Met) in two Turkish families with Parkinson's disease. *Parkinsonism Relat Disord* **89** (2021).
22. H. Liu, C. Koros, T. Strohäker, C. Schulte, M. Bozi, S. Varvaresos, A. Ibáñez de Opakua, A. M. Simitsi, A. Bougea, K. Voumvourakis, M. Maniati, S. G. Papageorgiou, A. Hauser, S. Becker, M. Zweckstetter, L. Stefanis, T. Gasser, A Novel SNCA A30G Mutation Causes Familial Parkinson's Disease. *Movement Disorders* **36**, 1624–1633 (2021).
23. P. Pasanen, L. Myllykangas, M. Siitonen, A. Raunio, S. Kaakkola, J. Lyytinen, P. J. Tienari, M. Pöyhönen, A. Paetau, A novel α -synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology. *Neurobiol Aging* **35** (2014).
24. C. Brücke, M. Al-Azzani, N. Ramalingam, M. Ramón, R. L. Sousa, F. Buratti, M. Zech, K. Sicking, L. Amaral, E. Gelpi, A. Chandran, A. Agarwal, S. R. Chaves, C. O. Fernández, U. Dettmer, J. Lautenschläger, M. Zweckstetter, R. F. Busnadiego, A. Zimprich, T. F. Outeiro, A novel alpha-synuclein G14R missense variant is associated with atypical neuropathological features. *medRxiv*, doi: 10.1101/2024.09.23.24313864 (2024).
25. A. B. Singleton, M. Farrer, J. Johnson, A. Singleton, S. Hague, J. Kachergus, M. Hulihan, T. Peuralinna, A. Dutra, R. Nussbaum, S. Lincoln, A. Crawley, M. Hanson, D. Maraganore, C. Adler, M. R. Cookson, M. Muentert, M. Baptista, D. Miller, J. Blancato, J.

- 098 Hardy, K. Gwinn-Hardy, α -Synuclein Locus Triplication Causes Parkinson's Disease.
099 *Science (1979)* **302** (2003).
- 000 26. J. Trinh, F. M. J. Zeldenrust, J. Huang, M. Kasten, S. Schaake, S. Petkovic, H. Madoev, A.
001 Grünewald, S. Almuammar, I. R. König, C. M. Lill, K. Lohmann, C. Klein, C. Marras,
002 Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35:
003 MDSGene systematic review. [Preprint] (2018). <https://doi.org/10.1002/mds.27527>.
- 004 27. T. Konno, O. A. Ross, A. Puschmann, D. W. Dickson, Z. K. Wszolek, Autosomal
005 dominant Parkinson's disease caused by SNCA duplications. *Parkinsonism Relat Disord*
006 **22** (2016).
- 007 28. C. Blauwendraat, M. B. Makarious, H. L. Leonard, S. Bandres-Ciga, H. Iwaki, M. A.
008 Nalls, A. J. Noyce, A. B. Singleton, A population scale analysis of rare SNCA variation in
009 the UK Biobank. *Neurobiol Dis* **148** (2021).
- 010 29. S. Petrucci, M. Ginevrino, E. M. Valente, Phenotypic spectrum of alpha-synuclein
011 mutations: New insights from patients and cellular models. *Parkinsonism Relat Disord* **22**
012 (2016).
- 013 30. A. Kapasi, J. R. Brosch, K. N. Nudelman, S. Agrawal, T. M. Foroud, J. A. Schneider, A
014 novel SNCA E83Q mutation in a case of dementia with Lewy bodies and atypical
015 frontotemporal lobar degeneration. *Neuropathology* **40** (2020).
- 016 31. C. Blauwendraat, D. A. Kia, L. Pihlstrøm, Z. Gan-Or, S. Lesage, J. R. Gibbs, J. Ding, R. N.
017 Alcalay, S. Hassin-Baer, A. M. Pittman, J. Brooks, C. Edsall, S. J. Chung, S. Goldwurm,
018 M. Toft, C. Schulte, C.-P. C. International Parkinson's Disease Genomics Consortium
019 (IPDGC), D. Hernandez, A. B. Singleton, M. A. Nalls, A. Brice, S. W. Scholz, N. W.
020 Wood, Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in Parkinson's
021 disease. *Neurobiol Aging* **64**, 159.e5-159.e8 (2018).

- 022 32. D. Papadimitriou, R. Antonelou, M. Miligkos, M. Maniati, N. Papagiannakis, S.
023 Bostantjopoulou, A. Leonardos, C. Koros, A. Simitsi, S. G. Papageorgiou, E. Kapaki, R. N.
024 Alcalay, A. Papadimitriou, A. Athanassiadou, M. Stamelou, L. Stefanis, Motor and
025 Nonmotor Features of Carriers of the p.A53T Alpha-Synuclein Mutation: A Longitudinal
026 Study. *Movement Disorders* **31** (2016).
- 027 33. H. Fujiwara, M. Hasegawa, N. Dohmae, A. Kawashima, E. Masliah, M. S. Goldberg, J.
028 Shen, K. Takio, T. Iwatsubo, α -Synuclein is phosphorylated in synucleinopathy lesions.
029 *Nat Cell Biol* **4**, 160–164 (2002).
- 030 34. N. Ramalingam, S.-X. Jin, T. E. Moors, L. Fonseca-Ornelas, K. Shimanaka, S. Lei, H. P.
031 Cam, A. H. Watson, L. Brontesi, L. Ding, D. Y. Hacibaloglu, H. Jiang, S. J. Choi, E.
032 Kanter, L. Liu, T. Bartels, S. Nuber, D. Sulzer, E. V. Mosharov, W. V. Chen, S. Li, D. J.
033 Selkoe, U. Dettmer, Dynamic physiological α -synuclein S129 phosphorylation is driven by
034 neuronal activity. *NPJ Parkinsons Dis* **9**, 4 (2023).
- 035 35. J. Li, V. N. Uversky, A. L. Fink, Effect of familial Parkinson’s disease point mutations
036 A30P and A53T on the structural properties, aggregation, and fibrillation of human α -
037 synuclein. *Biochemistry* **40** (2001).
- 038 36. M. B. Fares, N. Ait-Bouziad, I. Dikiy, M. K. Mbefo, A. Jovičić, A. Kiely, J. L. Holton, S.
039 J. Lee, A. D. Gitler, D. Eliezer, H. A. Lashuel, The novel Parkinson’s disease linked
040 mutation G51D attenuates in vitro aggregation and membrane binding of α -synuclein, and
041 enhances its secretion and nuclear localization in cells. *Hum Mol Genet* **23** (2014).
- 042 37. D. F. Lázaro, M. C. Dias, A. Carija, S. Navarro, C. S. Madaleno, S. Tenreiro, S. Ventura,
043 T. F. Outeiro, The effects of the novel A53E alpha-synuclein mutation on its
044 oligomerization and aggregation. *Acta Neuropathol Commun* **4** (2016).
- 045 38. T. S. Ulmer, A. Bax, N. B. Cole, R. L. Nussbaum, Structure and Dynamics of Micelle-
046 bound Human α -Synuclein. *Journal of Biological Chemistry* **280**, 9595–9603 (2005).

- 047 39. W. S. Davidson, A. Jonas, D. F. Clayton, J. M. George, Stabilization of α -Synuclein
048 Secondary Structure upon Binding to Synthetic Membranes. *Journal of Biological*
049 *Chemistry* **273**, 9443–9449 (1998).
- 050 40. D. Eliezer, E. Kutluay, R. Bussell, G. Browne, Conformational properties of α -synuclein in
051 its free and lipid-associated states 1 | Edited by P. E. Wright. *J Mol Biol* **307**, 1061–1073
052 (2001).
- 053 41. I. Walsh, F. Seno, S. C. E. Tosatto, A. Trovato, PASTA 2.0: an improved server for protein
054 aggregation prediction. *Nucleic Acids Res* **42**, W301–W307 (2014).
- 055 42. S. O. Garbuzynskiy, M. Yu. Lobanov, O. V. Galzitskaya, FoldAmyloid: a method of
056 prediction of amyloidogenic regions from protein sequence. *Bioinformatics* **26**, 326–332
057 (2010).
- 058 43. A. M. Thangakani, S. Kumar, R. Nagarajan, D. Velmurugan, M. M. Gromiha, GAP:
059 towards almost 100 percent prediction for β -strand-mediated aggregating peptides with
060 distinct morphologies. *Bioinformatics* **30**, 1983–1990 (2014).
- 061 44. R. Guerrero-Ferreira, N. M. I. Taylor, A. A. Arteni, P. Kumari, D. Mona, P. Ringler, M.
062 Britschgi, M. E. Lauer, A. Makky, J. Verasdock, R. Riek, R. Melki, B. H. Meier, A.
063 Böckmann, L. Bousset, H. Stahlberg, Two new polymorphic structures of human full-
064 length alpha-synuclein fibrils solved by cryo-electron microscopy. *Elife* **8** (2019).
- 065 45. B. Frieg, L. Antonschmidt, C. Dienemann, J. A. Geraets, E. E. Najbauer, D. Matthes, B. L.
066 de Groot, L. B. Andreas, S. Becker, C. Griesinger, G. F. Schröder, The 3D structure of
067 lipidic fibrils of α -synuclein. *Nat Commun* **13**, 6810 (2022).
- 068 46. S. Lövestam, M. Schweighauser, T. Matsubara, S. Murayama, T. Tomita, T. Ando, K.
069 Hasegawa, M. Yoshida, A. Tarutani, M. Hasegawa, M. Goedert, S. H. W. Scheres, Seeded
070 assembly in vitro does not replicate the structures of α -synuclein filaments from multiple
071 system atrophy. *FEBS Open Bio* **11** (2021).

- 072 47. D. F. Lázaro, E. F. Rodrigues, R. Langohr, H. Shahpasandzadeh, T. Ribeiro, P. Guerreiro,
073 E. Gerhardt, K. Kröhnert, J. Klucken, M. D. Pereira, B. Popova, N. Kruse, B. Mollenhauer,
074 S. O. Rizzoli, G. H. Braus, K. M. Danzer, T. F. Outeiro, Systematic Comparison of the
075 Effects of Alpha-synuclein Mutations on Its Oligomerization and Aggregation. *PLoS Genet*
076 **10**, e1004741 (2014).
- 077 48. A. Agarwal, A. Chandran, F. Raza, I.-M. Ungureanu, C. Hilcenko, K. Stott, N. A. Bright,
078 N. Morone, A. J. Warren, J. Lautenschläger, VAMP2 regulates phase separation of α -
079 synuclein. *Nat Cell Biol*, doi: 10.1038/s41556-024-01451-6 (2024).
- 080 49. N. Ramalingam, L. Brontesi, S. Jin, D. J. Selkoe, U. Dettmer, Dynamic reversibility of α -
081 synuclein serine-129 phosphorylation is impaired in synucleinopathy models. *EMBO Rep*
082 **24** (2023).
- 083 50. T. F. Outeiro, S. Lindquist, Yeast Cells Provide Insight into Alpha-Synuclein Biology and
084 Pathobiology. *Science (1979)* **302** (2003).
- 085 51. S. Richards, N. Aziz, S. Bale, D. Bick, S. Das, J. Gastier-Foster, W. W. Grody, M. Hegde,
086 E. Lyon, E. Spector, K. Voelkerding, H. L. Rehm, Standards and guidelines for the
087 interpretation of sequence variants: A joint consensus recommendation of the American
088 College of Medical Genetics and Genomics and the Association for Molecular Pathology.
089 *Genetics in Medicine* **17** (2015).
- 090 52. A. P. Kiely, H. Ling, Y. T. Asi, E. Kara, C. Proukakis, A. H. Schapira, H. R. Morris, H. C.
091 Roberts, S. Lubbe, P. Limousin, P. A. Lewis, A. J. Lees, N. Quinn, J. Hardy, S. Love, T.
092 Revesz, H. Houlden, J. L. Holton, Distinct clinical and neuropathological features of G51D
093 SNCA mutation cases compared with SNCA duplication and H50Q mutation. *Mol*
094 *Neurodegener* **10** (2015).
- 095 53. R. Krüger, W. Kuhn, K. L. Leenders, R. Sprengelmeyer, T. Müller, D. Voitalla, A. T.
096 Portman, R. P. Maguire, L. Veenma, U. Schröder, L. Schöls, J. T. Epplen, O. Riess, H.

- 997 Przuntek, Familial parkinsonism with synuclein pathology: Clinical and PET studies of
998 A30P mutation carriers. *Neurology* **56** (2001).
- 999 54. K. Kalinderi, V. Papaliagkas, L. Fidani, Surgicogenomics: The Role of Genetics in Deep
1000 Brain Stimulation in Parkinson's Disease Patients. *Brain Sci* **14**, 800 (2024).
- 1001 55. J. Youn, G. Oyama, N. Hattori, Y. Shimo, T. Kuusimäki, V. Kaasinen, A. Antonini, D.
1002 Kim, J. Il Lee, K. R. Cho, J. W. Cho, Subthalamic deep brain stimulation in Parkinson's
1003 disease with SNCA mutations: Based on the follow-up to 10 years. *Brain Behav* **12** (2022).
- 1004 56. M. H. Martikainen, M. Päivärinta, M. Hietala, V. Kaasinen, Clinical and imaging findings
1005 in Parkinson disease associated with the A53E SNCA mutation. *Neurol Genet* **1** (2015).
- 1006 57. M. Picillo, K. J. Lizarraga, E. L. Friesen, H. Chau, M. Zhang, C. Sato, G. Rooke, R. P.
1007 Munhoz, E. Rogaeva, P. E. Fraser, S. K. Kalia, L. V. Kalia, Parkinsonism due to A53E α -
1008 synuclein gene mutation: Clinical, genetic, epigenetic, and biochemical features. *Movement*
1009 *Disorders* **33** (2018).
- 1010 58. K. Senkevich, I. Miliukhina, A. Zhuravlev, M. Shumilova, M. Beletskaya, T. Skvortsova,
1011 E. Yu, J. Ahmad, F. Asayesh, Z. Gan Or, A. Emelyanov, S. Pchelina, Autosomal
1012 Dominant Parkinson's Disease Caused by *SNCA* p. E46K
1013 Mutation in a Family with Russian Ancestry. *Movement Disorders* **39**, 1424–1425 (2024).
- 1014 59. D. Eliezer, E. Kutluay, R. Bussell, G. Browne, Conformational properties of α -synuclein in
1015 its free and lipid-associated states. *J Mol Biol* **307** (2001).
- 1016 60. M. Rovere, J. B. Sanderson, L. Fonseca-Ornelas, D. S. Patel, T. Bartels, Refolding of
1017 helical soluble α -synuclein through transient interaction with lipid interfaces. *FEBS Lett*
1018 **592**, 1464–1472 (2018).
- 1019 61. U. Dettmer, Rationally Designed Variants of α -Synuclein Illuminate Its in vivo Structural
1020 Properties in Health and Disease. [Preprint] (2018).
1021 <https://doi.org/10.3389/fnins.2018.00623>.

- 122 62. R. J. Perrin, W. S. Woods, D. F. Clayton, J. M. George, Interaction of human α -synuclein
123 and Parkinson's disease variants with phospholipids: Structural analysis using site-directed
124 mutagenesis. *Journal of Biological Chemistry* **275** (2000).
- 125 63. E. Jo, N. Fuller, R. P. Rand, P. St George-Hyslop, P. E. Fraser, Defective membrane
126 interactions of familial Parkinson's disease mutant A30P α -Synuclein. *J Mol Biol* **315**
127 (2002).
- 128 64. G. Fusco, T. Pape, A. D. Stephens, P. Mahou, A. R. Costa, C. F. Kaminski, G. S. Kaminski
129 Schierle, M. Vendruscolo, G. Veglia, C. M. Dobson, A. De Simone, Structural basis of
130 synaptic vesicle assembly promoted by α -synuclein. *Nat Commun* **7** (2016).
- 131 65. N. J. Rutherford, B. D. Moore, T. E. Golde, B. I. Giasson, Divergent effects of the H50Q
132 and G51D SNCA mutations on the aggregation of α -synuclein. *J Neurochem* **131** (2014).
- 133 66. Y. C. Chi, G. S. Armstrong, D. N. M. Jones, E. Z. Eisenmesser, C. W. Liu, Residue
134 histidine 50 plays a key role in protecting α -Synuclein from aggregation at physiological
135 pH. *Journal of Biological Chemistry* **289** (2014).
- 136 67. S. Ray, N. Singh, R. Kumar, K. Patel, S. Pandey, D. Datta, J. Mahato, R. Panigrahi, A.
137 Navalkar, S. Mehra, L. Gadhe, D. Chatterjee, A. S. Sawner, S. Maiti, S. Bhatia, J. A.
138 Gerez, A. Chowdhury, A. Kumar, R. Padinhateeri, R. Riek, G. Krishnamoorthy, S. K.
139 Maji, α -Synuclein aggregation nucleates through liquid-liquid phase separation. *Nat Chem*
140 **12** (2020).
- 141 68. M. C. Hardenberg, T. Sinnige, S. Casford, S. T. Dada, C. Poudel, E. A. Robinson, M.
142 Fuxreiter, C. F. Kaminski, G. S. Kaminski Schierle, E. A. A. Nollen, C. M. Dobson, M.
143 Vendruscolo, Observation of an α -synuclein liquid droplet state and its maturation into
144 Lewy body-like assemblies. *J Mol Cell Biol* **13** (2021).
- 145 69. S. T. Dada, M. C. Hardenberg, Z. Toprakcioglu, L. K. Mrugalla, M. P. Cali, M. O.
146 McKeon, E. Klimont, T. C. T. Michaels, T. P. J. Knowles, M. Vendruscolo, Spontaneous

- 147 nucleation and fast aggregate-dependent proliferation of α -synuclein aggregates within
148 liquid condensates at neutral pH. *Proc Natl Acad Sci U S A* **120** (2023).
- 149 70. Y. Wu, B. Ma, C. Liu, D. Li, G. Sui, Pathological Involvement of Protein Phase Separation
150 and Aggregation in Neurodegenerative Diseases. *Int J Mol Sci* **25** (2024).
- 151 71. S. Ray, D. Chatterjee, S. Mukherjee, K. Patel, J. Mahato, Spatiotemporal solidification of
152 α -synuclein inside the liquid droplets. *bioRxiv* **4** (2021).
- 153 72. C. Wang, K. Zhang, B. Cai, J. E. Haller, K. E. Carnazza, J. Hu, C. Zhao, Z. Tian, X. Hu, D.
154 Hall, J. Qiang, S. Hou, Z. Liu, J. Gu, Y. Zhang, K. B. Seroogy, J. Burré, Y. Fang, C. Liu,
155 A. T. Brunger, D. Li, J. Diao, VAMP2 chaperones α -synuclein in synaptic vesicle co-
156 condensates. *Nat Cell Biol* **26**, 1287–1295 (2024).
- 157 73. E. Jo, J. A. McLaurin, C. M. Yip, P. St. George-Hyslop, P. E. Fraser, α -Synuclein
158 membrane interactions and lipid specificity. *Journal of Biological Chemistry* **275** (2000).
- 159 74. E. R. Middleton, E. Rhoades, Effects of curvature and composition on α -synuclein binding
160 to lipid vesicles. *Biophys J* **99** (2010).
- 161 75. C. R. Bodner, A. S. Maltsev, C. M. Dobson, A. Bax, Differential phospholipid binding of
162 α -synuclein variants implicated in Parkinson's disease revealed by solution NMR
163 spectroscopy. *Biochemistry* **49** (2010).
- 164 76. D. L. Fortin, V. M. Nemani, S. M. Voglmaier, M. D. Anthony, T. A. Ryan, R. H. Edwards,
165 Neural activity controls the synaptic accumulation of α -synuclein. *Journal of Neuroscience*
166 **25** (2005).
- 167 77. L. A. Parra-Rivas, K. Madhivanan, B. D. Aulston, L. Wang, D. D. Prakashchand, N. P.
168 Boyer, V. M. Saia-Cereda, K. Branes-Guerrero, D. P. Pizzo, P. Bagchi, V. S. Sundar, Y.
169 Tang, U. Das, D. A. Scott, P. Rangamani, Y. Ogawa, Subhojit Roy, Serine-129
170 phosphorylation of α -synuclein is an activity-dependent trigger for physiologic protein-
171 protein interactions and synaptic function. *Neuron* **111** (2023).

- 172 78. M. Al-Azzani, A. König, T. F. Outeiro, Production of Recombinant Alpha-Synuclein: Still
173 No Standardized Protocol in Sight. *Biomolecules* **12**, 324 (2022).
- 174 79. Y. Shen, A. Bax, Protein backbone and sidechain torsion angles predicted from NMR
175 chemical shifts using artificial neural networks. *J Biomol NMR* **56** (2013).
- 176 80. J. Schindelin, I. Arganda-Carreras, E. Frise, V. Kaynig, M. Longair, T. Pietzsch, S.
177 Preibisch, C. Rueden, S. Saalfeld, B. Schmid, J.-Y. Tinevez, D. J. White, V. Hartenstein,
178 K. Eliceiri, P. Tomancak, A. Cardona, Fiji: an open-source platform for biological-image
179 analysis. *Nat Methods* **9**, 676–682 (2012).
- 180 81. N. Ramalingam, U. Dettmer, Temperature is a key determinant of alpha- and beta-
181 synuclein membrane interactions in neurons. *J Biol Chem* **296**, 100271 (2021).

182

183 **Figures legends**

184 **Fig. 1. K58N mutation decreases the α -helical content affecting liposome binding.** a, $^1\text{H}, ^{15}\text{N}$
185 HSQC of αSyn WT (blue) and K58N (red). Evident CSPs are labeled. b, Combined HN/N CSPs
186 generated by the K58N mutation over the αSyn sequence. Affected region is highlighted in grey.
187 c, $\text{H}\alpha$ (green) and $\text{C}\alpha$ (black) CSPs. d, Normalized $^1\text{H}, ^{15}\text{N}$ HSQC intensity ratios. Error bars are
188 calculated from signal-to-noise ratios of individual resonances. e, Secondary structure
189 calculations from NMR chemical shifts for αSyn WT (α -helix, blue; β -strand, light blue) and
190 K58N (α -helix, red; β -strand, orange). On the right a zoom of the affected region with the α -
191 helical content is plotted. f, Micelle-bound αSyn structure (PDB ID: 1XQ8) with the positions of
192 the different pathological mutations highlighted. g, Residue specific α -helical content over 100 ns
193 MD simulations. Error bars indicate the standard error from 40 analyzed peptides. h-i, CD
194 experiments of WT (h) and K58N (i) αSyn at different protein:lipid ratios. j, Ellipticity change at
195 222 nm upon increasing concentrations of lipids for WT (blue) and K58N (red). More negative
196 values indicate a bigger increase of α -helical structure.

197

198 **Fig. 2. In vitro ThT-based aggregation assays for WT and K58N aSyn.** (A) and (B)

199 Aggregation kinetic profiles of WT and K58N aSyn. Data was normalized to the maximum

200 fluorescence value of each run. (C) Comparison of the half-time in min to for aggregation

201 kinetics. (D) Comparison of maximum ThT fluorescence values of WT and K58N. Error bars

202 represent mean \pm SD.

203

204 **Fig. 3. Characteristics of WT and K58N aSyn filaments.** A) TEM micrograph of WT aSyn

205 amyloid filaments. Black arrows mark selected filament ends. Scale bar: 100 nm. B) TEM

206 micrograph of K58N aSyn amyloid filaments. Black arrows indicate filament ends of exemplary

207 filaments. Scale bar: 100 nm. C) 2D class averages (706 Å box size) of twisting WT aSyn

208 filaments, illustrating the interaction between either two protofilaments (2PF) or a single

209 protofilament (1PF). Scale bar: 50 nm. D) 2D class averages (706 Å box size) reveal twisting

210 K58N aSyn filaments, again characterized by two protofilaments interacting with each other.

211 Scale bar: 50 nm. E) Overview of the electron density map of WT aSyn filaments. F) Overview of

212 the electron density map of K58N aSyn filaments. G) Amino acid sequence of human aSyn with

213 distinct regions color-coded (N-Terminus in orange, Non-amyloid component in purple, and C-

214 Terminus in green). H) The electron density map together with the atomic model of WT aSyn

215 amyloid filaments featuring a single beta-sheet layer formed by two interacting protofilaments.

216 The protofilament interface is stabilized by a K45-E57 salt bridge. I) The electron density map

217 together with the atomic model of K58N aSyn amyloid filaments. The protofilament interface is

218 again stabilized by the K45-E57 salt bridge. The mutated residue is indicated in red. J)

219 Superposition of the WT atomic model (grey) and the K58N mutant (blue). While the double-

220 arrow structure is similar, notable differences in the backbone highlight the impact of the K58N

221 mutation (residue marked in red) on the overall aSyn filament structure.

222

223 **Fig. 4. Effect of K58N mutation on inclusion formation in cells.** The patterns of inclusions
224 formation was investigated using SynT/Sph1 aggregation model, which is based on the co-
225 expression of based on the co-expression of WT or K58N SynT variants and synphilin-1. (A)
226 Immunohistochemistry images representing the inclusion formation in H4 cells expressing WT
227 and G14R aSyn. Scale bar: 20 μ m. (B) Quantification of the number of inclusions per cell and
228 their area (C). For each experiment, 50 cells were counted at a 100x magnification. The data
229 analysis was performed using a Student's t-test, and presented as mean \pm SD ($N=3$).

230

231 **Fig. 5. aSyn K58N shows decreased condensate formation in vitro and in cells.** (A) aSyn
232 phase separation in the presence of 2 mM Ca^{2+} and crowding with 15% PEG-8000, immediately
233 after PEG addition for aSyn wildtype (WT) and the disease variant aSyn K58N. aSyn
234 concentration used: 100 μ M. (B) Heatmap for turbidity measurements of aSyn phase separation in
235 the presence of 2 mM Ca^{2+} . Data derived from 4 independent repeats. (C) Condensate formation
236 of aSyn WT YFP and aSyn K58N YFP upon ectopic expression with VAMP2 in HeLa cells. aSyn
237 K58N YFP does not undergo condensate formation in cells. (D) Quantification of condensate
238 formation. Data derived from incuCyte screening, 16 images per well, 3 wells per biological
239 repeat, 3 biological repeats. n indicates biological repeats. Data are represented as mean \pm SD.
240 Unpaired two-tailed t-test.

241

242 **Fig. 6. Dynamic activity-dependent pS129 of K58N and WT aSyn.** (A) Schematic illustration
243 of aSyn structure exhibiting the KTKEGV repeat sequence harboring most familial PD mutations,
244 central hydrophobic domain, and C-terminal region. The sequence alignment of aSyn is displayed
245 below showing the conserved KTKEGV residues in yellow and sites of familial PD mutation in
246 orange. On the right, the experimental setup is summarized. (B) A representative western blot

247 (WB) displaying the levels of total aSyn and pS129 from DIV17-21 rat *SNCA*^{-/-} rat cortical
248 neurons expressing WT and G14R aSyn, with WB quantitative analysis presented below. (C) WB
249 results of WT and G14R transduced rat *SNCA*^{-/-} cortical neurons that were subjected to on-plate
250 sequential extraction to isolate the cytosolic (C) and membrane (M) fractions. MJFR1 antibody
251 was used for total aSyn detection, while GAPDH and Calnexin were used as cytosolic and
252 membrane fractions controls, respectively. (D) quantitative analysis of WT and K58N aSyn
253 solubility from WB data in (C). (E) A summary of the experimental conditions to study pS129
254 dynamic reversibility, with more information are provided in the main text. (F-G) Neuronal
255 activity-dependent reversible phosphorylation of S129 (as outlined in schematic E) was detected
256 in DIV17-21 rat *SNCA*^{-/-} cortical neurons expressing WT or G14R, respectively, following PTX
257 stimulation (20 μ M) and TTX inhibition (1 μ M). WB for quantifying total aSyn and pS129 was
258 employed and panels H-L are derived from F to G. (H) The percentage of increase in pS129,
259 compared to baseline, for WT and G14R aSyn observed after 2h or 4h PTX stimulation. (I)
260 Comparison of TTX-resistant pS129 levels in WT and G14R variants relative to baseline
261 conditions (DMSO vehicle). (J) The proportion of irreversible pS129 relative to the basal (DMSO
262 vehicle) condition. (K) The proportion of irreversible pS129 relative to 2 h PTX stimulation. (L)
263 The proportion of irreversible pS129 relative to 4 h PTX stimulation. **** $P < 0.0001$; *** $P <$
264 0.001 ; * $P < 0.05$; ns, not significant. The error bar was mean \pm SD.

265

266 **Fig. 7. Effect of K58N mutation on yeast cells.** *S. cerevisiae* cells harboring WT aSyn or K58N
267 aSyn mutation were grown to mid-log phase. (A) aSyn localization was analyzed by fluorescence
268 microscopy. (B) Cellular viability was evaluated by spotting assay, where cultures were spotted
269 on SD-URA agar plates.

270

271

272

273

274

275

276

277

278

279

280





281





282









283




284





285




A**B****C****D**



A**B****C**





A

EGFP

WT

K58N

**B** 10^{-1} 10^{-4}

EGFP

WT

K58N

